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ABSTRACT 
BIOPHYSICAL UNDERSTANDING OF NOVEL SYNTHETIC  
AMYLOID-β (Aβ) PRIONS IN ALZHEIMER`S DISEASE. 
by Amit Kumar 
August 2013 
Oligomers of amyloid-β (Aβ) peptide are the primary toxic agents that play a 
pivotal role in the pathogenesis of Alzheimer’s disease (AD).  Oligomers are the 
intermediates formed during the Aβ aggregation process leading up to insoluble fibrils.  It 
is important to know that oligomers can also be formed via pathways that do not lead to 
fibril formation. Such ‘off-pathway’ oligomers would have significantly longer half-lives 
than the ‘on-pathway’ ones, which may result in prolonged toxicity to neuronal cells.  
Furthermore, neither the mechanism of neurotoxicity nor the potential mechanisms of 
propagation and proliferation to neighboring cells are well understood. Moreover, recent 
in vivo studies on transgenic animal models have implicated a prion-like mechanism 
involved in the propagation of toxic oligomeric seeds.  Interfaces generated by lipids, 
fatty acids and other surfactants are well known to affect A  aggregation, especially in 
inducing alternate pathways. In this study, the effect of saturated non-esterified fatty 
acids (NEFAs) on the rate of A  aggregation was studied.  We have observed that 
NEFAs were able to induce an alternate pathway of aggregation, which was depended on 
NEFA concentrations. More importantly, in a narrow concentration range, NEFAs 
induced the formation of 12-18mers (Large Fatty Acid-derived Oligomers; LFAOs), 
which were isolable by size exclusion chromatography (SEC). We discovered that 
LFAOs can behave like prions, undergoing self-propagation, by quantitatively converting 
 iii 
monomeric Aβ into toxic LFAO assemblies in a template-assisted manner. We further 
analyzed the prion-like behavior of LFAOs by the ‘protein misfolding via cyclic 
amplification’ (PMCA) assay, as was done for prions.  Together, our findings indicate 
that LFAOs are unique Aβ prions and support the developing hypothesis that a common, 
prion-type mechanism of infectivity could be an underlying conserved mechanism among 
many neurodegenerative diseases. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
        Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder, 
which is mostly prevalent in the people above the age of 60.
4
  AD is the most common 
among all neurodegenerative disorders and other forms of dementia.  According to recent 
epidemiological data, it is estimated that around 4.5-5 million Americans are affected by 
AD, and this figure is predicted to increase to 11-16 million by 2050.
5
 
Figure 1. APP Cleavage and Aβ Generation. A) Bright-field immunohistochemistry 
showing deposits of plaques (dotted arrow) and neurofibrillary tangles (solid arrow) in 
the AD brain section.
1
 B) Schematic representation of extracellular release of A  after 
APP cleavage.
3
 C) APP (amyloid precursor protein) amino acid sequence with α-, β- 
and γ- secretases cleavage sites. The γ secretase can cleave at multiple sites to generate 
Aβ ranging from 39-43 amino acids. 
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The deposition of A  peptide aggregates primarily in the cortical and 
hippocampal regions of the brain is mainly responsible for the cognitive decline and 
memory loss that occur in AD.  The two classical hallmarks of the AD brain are neuritic 
plaques and neurofibillary tangles (Figure 1A).  Neuritic plaques are large, proteinacious, 
extracellular deposits, mainly composed of 40- and 42-amino acid long peptides (A 40 
and Aβ42, respectively) collectively called amyloid-  (A ) peptides.  Neurofibillary 
tangles are intracellular inclusions consisting of the aggregated form of hyper-
phosphorylated Tau protein.
4, 6-8
  Although both A  and Tau are known to be involved in 
the pathogenesis of AD, A  aggregation is largely believed to be the primary neurotoxic 
event in AD pathogenesis.  
A  peptides are generated by the sequential cleavage of a ubiquitously expressed, 
transmembrane protein called the amyloid precursor protein (APP; 770 amino acids) by 
aspartyl proteases - and - secretase (Figure 1B).  The initial cleavage of APP on the N-
terminal side by - secretase generates a large ectodomain and retains a 99-residue 
COOH-terminal fragment (CTF) within its transmembrane domain, which is then cleaved 
by - secretase, which releases the intracellular domain of APP into the cytoplasm and 
A  in the lumen (Figure 1B).
6, 8,9
  The - secretase is a multi-subunit protease complex 
that consists of presenilin-1 or presenilin-2, nicastrin, APH-1 (anterior pharynx-defective 
1), and PEN-2 (presenilin enhancer 2).
10
  The -secretase complex has a wide specificity 
and can cleave anywhere between the 711
th
 and 714
th
 residues in APP, corresponding to 
A 39 to 43 versions, among which A 40 and Aβ42 are the predominant forms (Figure 
1C).  Alternatively, instead of -secretase cleavage, another protease called α-secretase 
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that belongs to the A Disintegrin And Metalloproteinase (ADAM) family of proteases 
can cleave APP within the A  sequence (Figure 1C).  This releases a soluble N-terminal 
domain of APP called P3 containing 83 amino acids which possesses neurotrophic and 
neuroprotective properties.
6
   
AD is largely an idiopathic disorder, but a small percentage is familial, with 
mutations in specific genes that can lead to excessive deposition of A  in brain areas 
linked to memory and cognitive function.
2
  Genetic mutations in APP that lie outside the 
A  sequence (see Figure 2) give rise to early–onset familial AD (FAD).2  These 
mutations can lead to an increased production of the longer and more amyloidogenic 
form, A 42. 
 
 
Figure 2. APP Mutations Genetically Linked to Familial Alzheimer’s Disease (FAD) or 
Related Disorders. The sequence within APP that contains the Aß and transmembrane 
(TM) regions is expanded. The underlined residues represent the Aß1–42 peptide. The 
vertical dashed lines indicate the location of the TM domain. The letters below the 
wild-type sequence indicate the currently known missense mutations identified in 
certain patients with familial AD and/or hereditary cerebral hemorrhage with 
amyloidosis. Three-digit numbers refer to the codon number according to the ßAPP770 
isoform.
2
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A  Aggregation 
  Once generated, Aβ peptides can undergo aggregation, which is a nucleation-
dependent process analogous to crystal growth.  This process is characterized by the 
presence of a ‘lag-phase’, during which prerequisite conformational changes take place, 
followed by growth-phase towards fibril formation in a sigmoidal pattern (Figure 3).
11, 12, 
13
  During aggregation, the natively unstructured (random coil) monomeric A  undergoes 
conformational changes that result in a cross- -sheet structure observed in A  fibrils.  
The lag-phase can be eliminated by adding small amounts of pre-formed aggregates to 
monomers in a process called ‘seeding’.14 
Oligomers in A  Aggregation 
 Previously, it was believed that A  fibrils are mainly responsible for memory 
impairment and cognitive decline in AD, which led to the formulation of the ‘classical 
amyloid hypothesis’.15, 16  However this has been widely contested over the years after it 
became evident that cognitive decline occurred well before emergence of amyloid 
plaques in transgenic AD mouse brains.
17-22
  Several of such observations have resulted 
in a relatively new amyloid hypothesis that low molecular weight ‘soluble oligomers’ 
between ~2-60mers are the primary toxic agents in AD.  Consequently, several soluble, 
low-molecular weight oligomers were identified both in vivo as well as in vitro, which 
led to the isolation of many intermediates, including protofibrils (Figure 3).
12, 23-27
   Low 
levels of endogenous, soluble A  aggregates present considerable challenges in their 
identification and characterization; however, several species have been detected in the 
extracts of human AD brains that run as discrete bands on SDS-PAGE immunoblots.
19, 20, 
28, 29
  The molecular masses of these bands represent multimers of ~4 kDa A  monomers 
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and range from 2-10mers, and they are collectively called low-molecualr weight, soluble 
oligomers.  It has also been shown that these oligomers are not the broken fragments of 
larger aggregates that may be formed by SDS during SDS-PAGE analysis.
20, 28
  More 
recently, Shankar and coworkers fractionated the soluble extracts from human 
postmortem AD brains by superdex-75 size exclusion chromatography (SEC) and 
showed that dimeric A  caused memory impairment and synaptic dysfunction.
29
  
  This hypothesis was further confirmed by the identification of naturally secreted 
soluble oligomers that inhibit hippocampal long- term potentiation (LTP) in an AD 
transgenic mouse model and caused impaired cognitive decline.
30,31
  LTP is a measure of 
synaptic plasticity and its inhibition leads to synaptic dysfunction and cognitive decline.  
Lesńe and coworkers reported that 3-9 month old Tg2576 mice generated a series of 
oligomeric species with molecular weights corresponding to 6, 9, 12, and 15mers.  They 
 
 
Figure 3. Schematic Representation of A  Aggregation ‘On-pathway’. (Inset): The 
sigmoidal growth curve of the A  aggregation showing lag-phase and post- nucleation 
phase.  
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fractionated different species using a Superdex-75 SEC column and determined that a 
56kDa (12mer) species, termed as A *56, showed good correlation with the spatial 
memory deficits in Tg2576 mice.
28
  This was the first successful attempt to fractionate 
endogenous oligomers.  They claimed that the 12mers were exclusively responsible for 
the early synaptic dysfunction and cognitive decline observed prior to the emergence of 
plaques in AD mice.
28
 The soluble oligomers are thought to induce memory loss via 
synaptic dysfunction prior to cell death.
32
 
In another independent work, Townsend and colleagues showed A  trimers to be 
more potent in disrupting LTP than dimmers.
20
  They have identified a conditioned 
medium of the APP V717F-expressing Chinese hamster ovary (CHO) cell lines that form 
low-number oligomers intracellularly.  These naturally secreted soluble oligomers at 
picomolar concentrations could disrupt hippocampal LTP in the mammalian 
hippocampus.
20
  Podlisnky and coworkers claimed the detection of small amounts of 
SDS-stable A  oligomers in the culture media of CHO cells expressing endogenous 
amyloid beta-protein precursor genes.
33
  These oligomers were primarily identified as 
dimers and trimers by immunoprecipitation with a panel of A  antibodies which included 
rabbit antisera such as R1280 R1282 and R1963, as well as by electrophoretic co-
migration with synthetic A  oligomers and amino acid sequencing.  Selkoe and co-
workers developed protocols for separating secreted oligomers from cell culture by SEC 
under non-denaturing conditions.
20, 34, 35
  They fractionated A  monomers and oligomers 
generated and secreted by conditioned CHO cell medium by SEC and tested them 
separately on mouse hippocampal slices.  They found that trimers are more potent in 
inhibiting LTP as compared to dimers, suggesting the existence of a level of molecular 
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specificity in the interaction of A  oligomers with neuronal targets.  Most recently, Glabe 
and coworkers shown that fibrillar and prefibrillar oligomers may play a key role in 
preceding dementia in AD.
36
  
         Due to their increasing significance in AD pathology, it is becoming imperative to 
explore and understand the properties of low molecular weight, soluble A  oligomers.  
Endogenous Aβ oligomers are difficult to isolate and are present in extremely low 
amounts in physiological samples, making biophysical analyses a considerable challenge.  
Hence, many groups have focused on generating in vitro oligomers that can mimic 
endogenous ones.
28, 29, 33, 36-39
  Increasing interest in role of smaller oligomers in AD led 
to the generation of small diffusible Aβ42 oligomers, referred as A -derived diffusible 
ligands (ADDLs), which are mostly comprised of Aβ42 4-5mers.38  The 4-5mers were 
initially generated by co-incubating Aβ42 with a protein called clusterin and later by 
simply incubating Aβ42 in DMEM/F-12 hippocampal cell culture medium.37, 38  ADDLs 
were toxic to neuronal cells and inhibited LTP in rats.
38
  Later, Chromy and coworkers 
were successfully able to isolate and characterize these ADDLs using SEC and atomic 
force microscopy (AFM).  Results from these experiments indicated that they are fairly 
homogenous with an average height of ~ 5 nm in AFM.
40
  Additionally, fairly 
homogenous and soluble globular oligomers named ‘globulomers’ were generated by 
Barghorn and coworkers, which completely blocked LTP in rat hippocampal slices.  In 
order to generate these, they incubated the Aβ42 peptide in 7 mM SDS initially, diluted 
the solution to 1.8 mM SDS and dialyzed to remove SDS molecules, yielding 
globulomers in MW range of 38-50 kDa.
37
  Later, they showed that these globulomers are 
formed via a pathway that was different from the fibril formation pathway, termed as ‘off 
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pathway.
41
  Despite reasonable progress on in vitro oligomer generation, detailed 
mechanistic and biophysical information is still lacking, partly due to the difficulties 
involved in their generation itself. 
Amyloid Polymorphism and Structural Classification of Oligomers 
Recent studies have shown that amyloid fibrils are polymorphic, that a single 
polypeptide can fold into multiple amyloid conformations, and factors which can affect 
the rate limiting nucleation step can dictate the pathway of A  aggregation.
42
  This 
feature was first noted with mammalian and yeast prion proteins where it was observed 
that a single polypeptide can misfold into multiple amyloid conformations.
43
  Recently, 
two types of amyloid fibrils were formed by A 40 following aggregation under mildly 
agitated or quiescent conditions; chemical shift and line-width data from solid-state NMR 
for 33 of the 40 residues indicated different underlying structures.
44, 45
  They also showed 
that different fibril morphologies may have different underlying molecular structures, 
which was confirmed by AFM and electron microscopy (EM), that the predominant 
structure can be controlled by subtle variations in fibril growth conditions, and that both 
morphology and molecular structure are self-propagating when fibrils grow from 
preformed seeds.
44, 45
  
Furthermore, Glabe and coworkers classified the soluble oligomers into three 
structurally distinct classes based on their conformation as well as their ability to be 
recognized by certain conformation-specific antibodies.  These classes of oligomers are 
prefibrillar oligomers (PFO), fibrillar oligomers (FO) and annular protofibrils (APFs), 
which are recognized by A11, OC and PF specific antibodies respectively.
36
  FOs are 
small fibrillar fragments which can act as seeds for fibril formation and 
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elongate/aggregate mainly by monomer addition.  In contrast, PFOs are early 
intermediates of aggregation, specifically recognized by the oligomer-specific A11 
antibody.  PFOs can align themselves to form protofibrils, which undergo a conformation 
change to finally form fibrils.  Moreover, the N-terminal 6E10 epitope of PFOs has 
displayed polymorphism in acidic pH, which is completely unobserved at neutral pH.
46
  
On the other hand, APFs are a completely new and distinct class of oligomers, mainly 
characterized by pore-like structure and PF specific antibody. It has been shown that 
PFOs act as a precursor for APF formation, which are formed by circular arrangement of 
PFO subunits.
47
  These pore-like structure lead to membrane permeabilization and 
disruption of iron homeostasis causing cell death, a mechanism similar to bacterial pore-
forming toxins.
47
  
It is abundantly clear that structural variability in A  can arise from the conditions 
in which A  is aggregated.  Based on Glabe’s oligomer classification, several researchers 
attempted to determine whether the known in vitro and in vivo oligomers belong to the 
fibrillar or prefibrillar class of oligomers.  It has been observed that the in vitro generated 
oligomers ADDLs and globulomers are not detected by either PFO- or FO- specific 
antibodies.  Interestingly, anti-ADDL and anti-globulomer specific antibodies have 
shown very high reactivity with A  plaque deposits, suggesting that they may have an 
epitope similar to FOs, fibril type oligomers.
32, 48, 49
  In contrast, in vivo generated A *56 
isolated by Lesné and coworkers belongs to the prefibrillar oligomer class because they 
have shown high reactivity towards the A11 antibody on immunoblots.
28
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Interfacial Aggregation and Off-pathway Oligomers 
 A  aggregation is a nucleation dependent process as mentioned earlier, and this 
aggregation process can be affected by environmental factors such as pH, ionic strength, 
temperature, concentration etc.  In addition, the amphipathic nature of A  peptide 
induces preferential aggregation at hydrophilic/hydrophobic interfaces, indicating that 
interfaces may play a significant role in the A  aggregation.
50, 51
  Both physiological and 
non-physiological interfaces are well-known to affect to A  aggregation.  Nichols and 
coworkers have unambiguously demonstrated this interfacial phenomenon by showing 
that A 40 aggregation was accelerated by both polar-non polar interfaces as well as by 
microdroplets of  hexafluoro-2-propanol (HFIP). 
52,
 
53
  
Physiological interfaces such as those formed by biological membranes and 
anionic lipids are known to play important role in aggregation and oligomerization.
54, 55
  
Lipid rafts enriched with gangliosides such as GM1, GD1a, GD1b, and GT1b, along with 
cholesterol and sphingomyelins, are abundant in the brain and are known to affect A  
fibrillogenesis.
56-58
  These rafts are found largely but not exclusively in cell membrane 
domains known as caveolae.
55
  Importantly, the , and - secretases that generate A  
peptide from APP, as well as the A  peptides themselves, are concentrated in lipid rafts, 
suggesting that lipids may play pivotal role in A  amyloidogenesis.
56-58
  Moreover, lipids 
and lipid metabolites present in amyloid deposits have the potential to affect several areas 
of amyloid metabolism, including the formation, stability, morphology, and toxicity of 
fibrils.
59-61
  Many studies have focused on lipid bilayers and membrane surfaces where 
the effect of lipids on A  fibril formation is variable and depends on the protein/lipid 
11 
 
 
ratio and the degree of membrane penetration.
62
  But generally it is accepted that A  
fibril formation is enhanced by the presence of a negatively charged lipid surface.
59, 61, 62
  
Peroxidized lipids and their derivatives such as 4-hydroxynonenal are involved in 
promoting A  deposition, linking oxidative stress to amyloid deposition.
63
  It has also 
been shown that biological lipids present in the brain can revert inert A  plaques or 
fibrils into highly toxic oligomers, which causes memory deficits in mice.
64
  The 
interaction of sialic acid with A  can also promote toxic oligomer formation by inducing 
peptide conformational change.
65
  Furthermore, it has also been observed that neuronal 
receptors that bind to A  oligomers are mainly embedded in lipid rafts, promoting 
toxicity.
66
 
In vitro interactions of A  with glycosphingolipids, such as GM1ganglioside, in 
which micelles and reconstituted liposomes act as rafts to promote A  binding and -
sheet structure have been reported.
67-69
  Biological membranes can also promote the 
aggregation of A  because of the presence of abundant amounts of phospholipids with 
polar head groups that can provide an anionic micellar interface.  But the interaction of 
A  with these anionic phospholipids/sphingolipid vesicles is limited to polar head groups 
without penetration of A  into bilayer.
70, 71
  The rate of A  aggregation at an anionic 
micellar interface can be compared to the rate of aggregation at polar-nonpolar interface 
using a detergent, sodium dodecyl sulfate (SDS), Although SDS-PAGE analysis is most 
commonly used as a technique to identify endogenous, soluble A  oligomers and SDS is 
considered as a denaturant that can destroy native protein structure, in low concentrations 
it can provide an anionic, micellar interface that has been shown to increase A  
12 
 
 
aggregation.
72
  In contrast, SDS concentrations well above the critical micelle 
concentration (CMC) restrict the peptide in a α-helical structural conformation that does 
not aggregate.
73, 74
  Moreover, Rangachari and coworkers have concluded that Aβ42 
rapidly forms oligomers as opposed to protofibrils in concentrations below the CMC of 
SDS by distinct pathway that they called the “off pathway”.  These observations 
indicated that the aggregation pathway depends upon the SDS: A  ratio.
73-76
  
These published reports indicate that interfaces generated by lipids can alter the 
A  aggregation pathway and, more importantly, can generate toxic oligomers as off-
pathway products and play a pivotal role in promoting the exclusive formation of 
neurotoxic oligomers. 
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Prion-type Propagation Mechanism –  
Conserved Among Neurodegenerative Diseases? 
The process of self-propagation is well known among prion diseases, which are 
also called ‘spongiform encephalopathies’.  The most common ones are Creutzfeldt-
Jakob disease (CJD) and Kuru disease in humans as well as Bovine spongiform 
encephalopathy (BSE) and scrapie in animals.  In prion disease, the normal prion protein 
in its non-toxic, cellular form, PrP
C
, converts to a misfolded and infectious scrapie form, 
PrP
Sc
.  PrP
Sc 
is responsible for the propagation of the disease.  Prion propagation is a 
continuous process, in which newly formed PrP
Sc 
act as template for further initiating the 
misfolding to continue prion propagation.
77, 78
  This ‘protein only’ hypothesis of prion 
infectivity was first introduced by Griffith in 1967.
79
   It is now believed that a similar 
protein corruptive mechanism may be also involved in the pathophysiology of other 
neurodegenerative disorders like Parkinson’s disease (PD), frontotemporal lobar 
dementia (FTLD) and amyotrophic lateral sclerosis (ALS).  Desplats and coworkers have 
shown that α-synuclein involved in PD can migrate and infect neighboring neurons and 
form lewy bodies, suggesting a prion like propagation mechanism.
80
  More recently, 
Christian and coworkers have shown that extracellular α-synuclein can enter cells by 
endocytosis and act as ‘seed’ to promote the aggregation of intracellular α-synuclein in 
mouse models, further indicating the involvement of prion like corruptive propagation.
81
  
Similar types of behavior have been also reported for the mutant of superoxide dismutase 
(SOD1) and TDP43 protein involved in ALS and FTLD, respectively.
82, 83, 84
   In the AD 
field, self-propagation of oligomers is a fairly new and underexplored concept, which 
requires a great deal more understanding and verification.  So far, only a few reports have 
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been published showing that in vitro generated oligomers can undergo replication to 
generate a similar type of oligomers from monomers on seeding.  FOs and PFOs have 
been shown to undergo self-replication, generating similar type of oligomers from 
monomer.
85, 86
  
Several in vivo studies demonstrate that the self-propagation behavior of A  
amyloids is similar to prions.  Jucker and coworkers have shown that brain extract 
containing A  from AD patients or -amyloid precursor protein (APP) transgenic mice 
produce cerebral -amyloidosis and other related pathologies in the transgenic APP 
mouse model in a time and concentration dependent manner following exogenous 
induction.
87
  Later on, they have also shown that these exogenous seed have similar 
properties to the PrP
Sc 
form of prion protein.
88
  More recently, Stoehr and coworker have 
shown that A  aggregates, whether purified from brain extract or formed from synthetic 
A , act as prions by inducing widespread cerebral -amyloidosis.
89
  These findings 
clearly indicate and further support the current hypothesis that ‘template-assisted 
corruptive’ protein propagation could be the common mechanism of disease progression 
and toxicity in all of these neurological disorders.  Unfortunately, research so far has been 
very segregated, failing to give a clear picture of disease pathology and provide a 
perspective on clinical significance/implications.   
Despite the emerging wealth of information regarding soluble oligomers, several 
molecular level questions still remain that need to be answered.  Some of these are: 
1.  Are there any similarities/dissimilarities between off- and on-pathway 
intermediates?  
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2. Is there an underlying mechanism of self propagation and toxicity that is 
conserved among all neurodegenerative diseases?  
3. What is the structure of pathogenic oligomeric seed? 
4. Is propagation specific to off-pathway intermediates? 
5. Is propagation the property of a specific conformation of seed?  If so, what is the 
optimum threshold concentration of ‘seed’ required to initiate propagation?  
6. What external parameters can affect prion-type propagation?  
My current research efforts will be focused on understanding some of these 
questions, which will provide insights into the mechanism of AD pathology.  My findings 
may also open doors for the development of new diagnostic strategies and help to 
counteract disease progression through presymptomatic detection and prevention.    
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CHAPTER II 
MATERIALS AND METHODS 
Wild type (WT) and Dansyl (Dan) Aβ42 were synthesized by the Peptide 
Synthesis Facility at the Mayo Clinic (Rochester, MN) using routine Fmoc chemistry.  
MALDI-TOF mass spectrometry revealed >90% purity of both peptides.  SDS and 
thioflavin-T (ThT) were procured from Sigma (St. Louis, MO).  All saturated fatty acids 
were purchased as sodium salts from NuCheck Prep Inc (Elysian, MN).  Monoclonal 
Ab9/Ab5 antibody specific for Aβ1-16 was supplied by the Mayo Clinic (Rochester, 
MN).  The 1 X 30-cm superdex-75 HR 10/30 SEC column was purchased from GE Life 
Sciences.  Gel electrophoresis and blotting instruments and buffers were procured from 
Bio-Rad Laboratories, Inc.  All other chemicals were obtained from VWR Inc.  
Preparation of Aβ42 Monomers 
Lyophilized stocks of synthetic Aβ42 were stored at -20 C, desiccated.  Briefly, 
1.5- 2 mg of peptide was dissolved in 0.5 ml of 35 mM NaOH and stored for 15 minutes 
at room temperature prior to size exclusion chromatography (SEC) on a 1  30 cm 
Superdex-75 HR 10/30 column (GE Life Sciences) attached to an AKTA FPLC system 
(GE Healthcare, Buckinghamshire) to remove any preformed aggregates as previously 
reported.
90
  The column was pre-equilibrated in 20 mM Tris-HCl buffer (pH 8.0) at 25 C 
and was run at a flow rate of 0.5 ml/min.  One minute fractions were collected.  
Concentrations of A  were determined by UV-Vis spectrometry on a Cary 50 
spectrophotometer (Varian Inc) using a molar extinction coefficient of 1450 cm
-1
M
-1
 at 
276 nm (www.expasy.org), corresponding to the single tyrosine residue in A 42. Peptide 
integrity after SEC was again confirmed by MALDI-TOF mass spectrometry. Which 
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shows a monoisotopic molecular mass of 4516.31 Da in a good agreement with a 
calculated mass of 4513.13 Da. Monomeric Aβ42 fractions were stored at 4 oC and used 
within 2 to 5 days of SEC purification in all experiments to avoid any preformed 
aggregates in our reactions.  
Aβ Aggregation Reactions 
All reactions and measurements were made at room temperature unless otherwise 
noted.  Reactions were initiated in siliconized Eppendorf tubes by incubating appropriate 
concentrations of freshly purified Aβ42 monomer in buffer without agitation.  
Aggregation kinetic parameters were obtained by monitoring the reaction with ThT and 
fitting fluorescence data points to the sigmoidal curve in Eq. 1 using Origin 7.0.
91
        
                                         Eq. 1               
 
In this equation t is time, a and b are fixed parameters, and t0.5 is the time to reach half-
maximal ThT fluorescence.  Data points were unweighted.  Lag times were equal to t0.5 − 
2b for each fitted curve.   
Measurement of Critical Micelle Concentration (CMC)  
CMCs of fatty acids were determined using N-phenyl-1-naphthylamine (NPN) 
from Sigma (St. Louis, MO) as a fluorescent probe.  Fluorescence measurements of NPN 
in the presence of fatty acids were acquired at the excitation wavelength of 340 nm while 
scanning emission wavelengths ranging from 400-500 nm on a Cary Eclipse fluorescence 
spectrometer (Varian Inc.).  Fatty acid mixtures contained 0.5-170 mM fatty acid along 
with 50 mM NaCl in 10 mM Tris buffer, pH 8.0.  NPN was added to a total concentration 
18 
 
 
of 1.5 µM and the solution was incubated for 30 minutes at 37 
o
C.  The data points were 
fitted to obtain a linear curve using Origin 7.0.  
Seeding Experiments  
Monomeric Aβ42 (25 M) was incubated alone or with different concentration of 
fatty acids in buffer containing 50 mM NaCl and 20 mM Tris pH 8.0.  After 48 hours, 
10% (m/v) seed of the incubated sample were withdrawn and mixed with fresh 
monomeric Aβ42 (25 M) and incubated at 37 C under quiescent conditions along with 
a control without seed.  The rate of Aβ42 aggregation was monitored using the ThT 
assay.   
Gn-HCl Denaturation Experiments   
The thermodynamic stability of oligomers formed in the presence of fatty acids 
was determined by guanidine-HCl (GnHCl) denaturation.  Aβ42 (25 M) samples in the 
presence of specific concentrations of fatty acids (to generate 12-18mers or 4-5mers) 
were incubated at 37 C.  Aliquots of the samples were taken after 48 hours of 
incubation, and tyrosine intrinsic fluorescence was measured using λex 276 nm and 
scanning the emission spectrum (λem) between 300-400 nm with an excitation/emission 
slit widths of 10/10 nm on a Cary Eclipse fluorescence spectrometer (Varian Inc).  The 
sample was then subjected to denaturation by titrating with 6 M GnHCl within the 
fluorescence cuvette, at room temperature.  The scans were averaged three times to 
minimize error.  Control spectra were measured by adding buffer without fatty acids to 
buffered 25 M Aβ42 using the same volumes of GnHCl, which were subtracted from 
the sample spectra.  The area under the curve of the blank-corrected spectra was plotted 
against the GnHCl concentration.  The data were then normalized against the lowest and 
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highest fluorescence intensity for the given fatty acid concentration.  Three such blank-
corrected spectra were averaged and are represented here.  The resulting curve is fitted 
using the following Boltzman equation: 
92
  
      Eq. 2 
Where, A1 and A2 are constants, C is the concentration of the denaturant and CM is the 
mid-point of the curve, which is considered to be the concentration of melting.  The data 
was processed using Origin 7.0. 
Preparation and Isolation of LFAOs 
  Freshly purified Aβ42 (50 μM) was incubated with 50 mM NaCl and 5 mM C12 
fatty acid at 37 C for 48 hours.  After 48 hours, the sample was spun at 19,000 x g for 20 
minutes, and the supernatant was subjected to SEC; the peaks near the void volume (Vo) 
fractions were collected.  Concentrations of collected fractions were determined by UV 
absorbance with a molar extinction coefficient of 1450 cm
-1
M
-1
 at 276 nm.  All isolated 
LFAO fractions were stored at 4 
o
C and used within 2-4 days after SEC isolation in all 
experiments. 
Agitation Experiments with Hexane-buffer and Chloroform-buffer Interfaces   
To freshly purified 2 μM LFAO or Aβ42 monomer (control) in 20 mM Tris, pH 
8.0, 5% (v/v) hexane (ρ = 0.6548 g/ml) or chloroform (ρ = 1.483 g/ml) were added 
independently and mixed vigorously using a vortex mixer (VWR Inc) for 1 minute of 
agitation followed by 5 minutes rest. After eight cycles of agitation (~ 1 hour), the 
samples were then dialyzed against 20 mM Tris-HCl (pH 8.0) at 25 C using a 2-kDa-
MWCO Slide-A-Lyzer G2 dialysis cassette (Thermo Scientific) for 23 hours. Afterward, 
20 
 
 
the dialyzed samples were subjected to immunoblotting, dynamic light scattering (DLS) 
and atomic force microscopy (AFM) analyses. 
Suspension Experiment with Chloroform-buffer Interface   
The suspension method reported previously was followed  in our experiments.
93
  
Freshly purified 2 μM LFAO or Aβ42 monomer (control) (0.3 mL) was suspended on top 
of 100% chloroform solution (0.3 mL) in a 1.5 mL siliconized Eppendorf tube without 
mixing.  The samples were kept at 25 C for 24 hours without any disturbance.  After 24 
hours, the samples were removed just above the interface, without disturbing the 
interface.  The samples from both reactions were subjected to immunoblotting, DLS, and 
AFM analyses. 
LFAO Propagation Experiment   
Monomeric Aβ42 (20 μM) was incubated alone or with 2% (0.4 μM) LFAO seed 
in 20 mM Tris pH 8.0 at 25 C for 72 hours.  Aliquots of the samples were removed at 0, 
24, 48 and 72 hours and then subjected to immunoblotting and AFM after spinning at 
19,000 x g for 20 minutes.  The 0.4 μM LFAO seeds alone were used as a control.  
Similarly, for SEC isolation of replicated LFAO, 50 μM Aβ42 monomer was incubated 
with 1 μM LFAO under the same conditions, keeping the A 42: LFAO ratio the same.  
Aliquots of samples were removed at 0, 24, 48 and 72 hours and subjected to SEC on a 
Superdex-75 HR 10/30 column after spinning at 19000 x g for 20 minutes to remove 
fibrils.  Fraction 17 from each SEC fractionation at 0, 24, 48 and 72 hours was subjected 
to immunoblotting and circular dichroism (CD). 
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LFAO propagation experiment with Dansyl-Aβ42monomer  
 The above experiment was repeated with Dansyl-Aβ42 (Dan-A 42) monomer, 
which was purified similarly to wild-type Aβ42, as mentioned above.  Freshly purified 50 
μM Dan-Aβ42 monomer was incubated with 1 μM LFAO under the same conditions as 
mentioned above.  Aliquots of samples were removed after 72 hours and subjected to 
SEC on a Superdex-75 HR 10/30 column after spinning at 19,000 x g for 20 minutes to 
remove fibrils.  Fractions 17 and 18 from the SEC fractionation were subjected to 
immunoblotting and emission fluorescence spectroscopy using a Cary Eclipse 
fluorescence spectrometer (Varian Inc.) in scan mode.  Dansyl emission was monitored at 
450 nm after exciting at 350 nm using 10-nm slits. 
Amplification of LFAOs 
For Cycle-1, monomeric Aβ42 (50 μM) was incubated with 2% (1 μM) LFAO 
seed in 20 mM Tris pH 8.0 at 25 C for 72 hours.  After 72 hours, the sample was 
centrifuged at 19,000 x g for 20 minutes to remove any fibrils, and the supernatant was 
loaded on a Superdex-75 HR 10/30 SEC column to isolate R-LFAOs.  Fractions 16 and 
17 after SEC fractionation were collected and subjected to immunoblotting to confirm the 
presence of R-LFAOs.  For Cycle-2, 50% v/v R-LFAOs (Fraction 16) were used as seed 
and incubated with 50 μM monomeric Aβ42 for 96 hours at room temperature.  After 96 
hours, the supernatant was subjected to SEC after spinning at 19,000 x g for 20 minutes 
to remove fibrils.  Fractions 16 and 17 were collected.  For Cycle-3, 50% v/v R-LFAOs 
from Cycle-2 (Fraction 16) were again used as seed and incubated with 50 μM 
monomeric Aβ42 for 212 hours at room temperature, followed by SEC after spinning at 
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19000 x g for 20 minutes to remove fibrils.  The quantitative fold increase after each 
cycle was calculated by comparing the SEC profile of seeded sample with seed alone. 
Generation and Isolation of Replicated LFAO (R-LFAO) 
Monomeric Aβ42 (50 μM) was incubated with 5% (2.5 μM) LFAO seed in 20 
mM Tris pH 8.0 at 25 C for 72 hours.  After 72 hours, the sample was subjected to SEC 
onto a Superdex-75 HR 10/30 column after spinning at 19,000 x g for 20 minutes to 
remove fibrils.  Fractions 16 and 17 from the SEC fractionation were collected and 
subjected to immunoblotting to confirm the presence of R-LFAOs. 
Determination of LFAO Threshold Concentration for Self-Propagation 
Monomeric Aβ42 (30 μM) was incubated alone or with 0.2, 2 and 20% (molar 
ratio) LFAO seeds in 20 mM Tris pH 8.0 at 25 C for 212 hours.  The aliquots of samples 
were removed at 72, 144 and 212 hours and subjected to immunoblotting and SEC on a 
Superdex-75 HR 10/30 column after spinning at 19,000 x g for 20 minutes.  The molar 
equivalents of 0.2, 2 and 20% (molar ratio) LFAO seeds alone were also used as a 
control.  The quantitative fold increase after each time point was calculated by comparing 
the SEC profile of seeded sample with seed alone. 
Effect of Temperature on LFAO 
Freshly isolated LFAOs (7 μM) was heated at varying temperatures ranging from 
10-120 C for 5 minutes and allowed to equilibrate to room temperature followed by 
immunoblotting and dynamic light scattering (DLS) analysis.  The LFAO’s CD spectra 
were also collected at 10-100 C in the far UV region with a Jasco J-815 
spectropolarimeter (Jasco Inc, Easton, MD).  LFAO samples were placed in a 0.1 cm 
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path-length quartz cuvette (Hellma) and monitored in continuous scan mode (260-190 
nm).   
To study the effect of temperature on LFAO self-propagation efficiency, 
monomeric Aβ42 (30 μM) was incubated alone or with 0.6 μM unheated or 80, 100, or 
120 C heated LFAO seeds in 20 mM Tris pH 8.0 at 25 C for 72 hours.  The supernatant 
samples were then subjected to immunoblotting and SEC on a Superdex-75 HR 10/30 
column after spinning at 19,000 x g for 20 minutes.  The 0.6 μM LFAO seeds alone were 
also used as a control. The quantitative fold increase after 72 hours was calculated by 
comparing the SEC profile of seeded sample with seed alone. 
Statistical Analysis 
Dixon’s Q test was applied to the absorbance measurements of the R-LFAOs to 
remove outliers with greater than 95% certainty.  Quantitative fold increase was 
calculated by dividing the absorbance of the R-LFAO’s SEC peaks by the averaged 
absorbance of at least three measurements of seed alone.  Levene’s test (95% certainty) 
was used to test for homogeneity of variance among fold increase, and a one-way 
ANOVA followed by Tukey’s HSD (Honestly Significant Difference) was used to 
determine confidence intervals for each time/seed combination. 
Fluorescence Spectroscopy  
ThT fluorescence (F) was monitored in a microcuvette with a Cary Eclipse 
fluorescence spectrometer (Varian Inc) after 15-fold dilution of Aβ42 samples into 5 mM 
Tris-HCl (pH 8.0) containing 10 μM ThT.  Continuous measurements of F were taken for 
1 minute with the excitation and emission wavelengths fixed at 450 and 482 nm 
respectively, and the excitation and emission slits set at 10 nm. 
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Dynamic Light Scattering (DLS) 
    DLS was performed on a Zetasizer Nano S DLS instrument (Malvern Inc., 
Worcestershire, UK) in Dr. Gordon Cannon’s lab (USM).  Each sample measurement 
consisted of 6 runs of 10 seconds each with a pre-equilibration time of 40 seconds. After 
the measurement, the number (%) was exported and plotted against size (diameter, nm) 
using Origin 7.0 software.   
Polyacrylamide Gel Electrophoreses (PAGE) and Immunoblotting 
    Samples were dissolved in loading buffer (1X Laemmli buffer) containing 1% 
SDS, applied without heating to 4-12% NuPAGE gels (Invitrogen) containing bis-Tris, 
and resolved in MES running buffer with 0.1% SDS.  Dye-linked MW markers (Blue 
Plus2 Prestained Standards, Invitrogen) were run in parallel for calibration.  Gels were 
electroblotted onto 0.45 m Immobilon nitrocellulose membranes (BioTrace
TM
 NT, Life 
Sciences Inc).  Blots were boiled in a microwave oven in PBS for 2 minutes and were 
blocked overnight with 1X PBS containing 5% nonfat dry milk and probed (1-2 hours) 
with 1:1000-1:2500 dilutions of monoclonal Ab9 antibod, which detects amino acid 
residues 1-16 of A . Blots were then incubated with anti-mouse horseradish peroxide 
(HRP) conjugate and developed with ECL reagent (Thermo Scientific).  
Atomic Force Microscopy (AFM) 
AFM was done in our collaborator Dr. Sarah Morgan’s lab in the School of 
Polymers and High Performance Materials at USM.  Mica was cleaved using a razor 
blade and taped to a magnetic sample holder.  The mica stub was then covered with a 3-
aminopropyl-triethoxy silane (APTES) solution (500 μL APTES in 50 mL 1mM acetic 
acid) for 15 minutes.  The APTES solution was then decanted, and the mica was rinsed 
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with 150 μL of deionized water four times.  After rinsing, the mica stub was dried with 
compressed N2 gas and stored in a desiccator for one hour.  Next, 150 μL of 0.1-0.25 μM 
A  sample was added to the mica and allowed to adsorb for 20 minutes.  The sample was 
then decanted and the mica stub was rinsed with 150 μL of deionized water four times.  
Finally, the mica stub was dried with compressed N2 gas and stored in a desiccator until 
imaging.  The surface topography of each sample was explored by imaging the peptide 
after it had been adsorbed onto APTES treated freshly cleaved mica.  These images were 
obtained via an Agilent 5500 AFM (Agilent Technologies) in tapping mode, using 
RTESP-etched silicon probes (length: 125 µm, nominal force constant: 40 N/m, and 
resonance frequency: 275 kHz) (Veeco Instruments).  While under ambient 
environmental conditions, the scan rate was held constant at 1 Hz.  All standard image-
processing techniques were performed on Nanoscope version 5.30r2 image analysis 
software.  Nanoscope and Gwyddion version 2.7 software were used to calculate feature 
heights by two methods: 1) section analysis to extract height profiles and 2) particle 
analysis to determine the statistical distribution of pixel heights for individual aggregates.  
Multiple areas were imaged for each sample and while height, phase and amplitude 
images were collected simultaneously, only representative amplitude images are 
presented. 
Analytical Ultracentrifugation (AUC) 
AUC was done in our collaborator Dr. Jack Correia’s lab in Department of 
Biochemistry at University of Mississippi Medical Center (UMMC). 
sample preparation. FITC-labeled Aβ42 (FITC-A 42) was purchased in a lyophilized 
form (Bachem Inc.) and stored at – 20 C prior to use.  A stock containing 5 mM FITC-
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Aβ42 in DMSO stock was prepared as described previously.41  The DMSO stock was 
then diluted to 100 μM in 20 mM Tris (pH 8.0) and used for generating FITC-labeled 
LFAO (FITC-LFAO).  Briefly, for the generation and isolation of FITC-LFAO, 40 μM 
wild type Aβ42 (WT- A 42) and 10 μM FITC- Aβ42 was mixed in 1:4 ratio and 
incubated with 5 mM C12:0 fatty acid under the same conditions as described above for 
LFAO preparation, and LFAOs were isolated using a similar protocol.  For propagation 
experiments, monomeric Aβ42 (20 μM) was incubated with 2% (0.4 μM) FITC-LFAO 
seed in 20 mM Tris pH 8.0 at 25 C for 72 hours.  After 72 hours, the sample was 
subjected to sedimentation velocity analysis.  The 0.4 μM FITC-LFAO seeds alone were 
used as a control.  Similarly, FITC-fibrils were prepared by mixing 45 uM WT- Aβ42 
with 5 μM FITC-Aβ42 and incubated with 150 mM NaCl in 20 mM Tris pH 8.0 at 37 C 
for 2-3 days.  The ThT fluorescence was monitored daily until it reached a plateau.  The 
sample was then centrifuged at 19,000 x g for 20 minutes.  The pellet was resuspended in 
20 mM Tris (pH 8.0) and used for AUC analysis. 
sedimentation velocity.  Samples were mixed by brief vortexing and then spun in a 
tabletop centrifuge for approximately 5 seconds to ensure that no sample was lost on the 
walls of the tube.  Samples were then loaded into 1.2 cm path length sedimentation 
velocity cells (Sedvel60) and placed in an XL-A Analytical Ultracentrifuge modified to 
accept a fluorescence detection system (Aviv FDS).  The temperature on the centrifuge 
was equilibrated until it remained constant at 20 
o
C for at least 5 minutes.  The centrifuge 
was then accelerated to 5,000 rpm, where the focus depth and gain for the fluorescence 
detection system were adjusted to maximize the signal collected.  The centrifuge was 
then accelerated to 60,000 rpm, and data collection began immediately after final velocity 
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was reached.  Each scan was averaged over 5 consecutive scans to increase the signal to 
noise ratio.  The run was stopped when the fluorescence intensity vs. radial distance 
profiles remained constant between scans, indicating that the boundary had pelleted.  The 
samples were then re-run for approximately 30 minutes at 60K using absorbance optics to 
collect pseudo absorbance data.  All data was transferred to a separate computer for 
analysis; the pseudo-absorbance data was used to calculate the meniscus position for each 
sample using the meniscus wizard in the software program DCDT2+ (version 2.3.2).
94
  
The software program Sedfit (Sedfit89) was used to generate c(s) distributions for the 
FDS data with 0.1 S resolution.
95
   The c(s) distribution for each sample was integrated 
and divided by the area, and all data are presented as normalized c(s) distributions.  The 
software program Sedfit was also used to generate c(M) distribution after generating the 
c(s) distribution by assuming a constant diffusion coefficient for all samples and an f/fo 
value of 1.2.  The c(M) distributions were normalized using the same methods as 
described for c(s) distributions. 
Circular dichroism (CD) 
            CD spectra were obtained in the far UV region with a Jasco J-815 
spectropolarimeter (Jasco Inc, Easton, MD).  Samples were placed in a 0.1 cm path-
length quartz cuvette (Hellma) and were monitored in continuous scan mode (260-190 
nm).  The acquisition parameters were 50 nm/min with 8 seconds response time, 1 nm 
bandwidth and 0.1 nm data pitch, and data set were averaged over two scans.  Spectra of 
appropriate blanks were subtracted from data set as indicated.  The corrected, averaged 
spectra were smoothed using the ‘mean-movement’ algorithm with a convolution width 
of 25 using the Jasco spectra analysis program.  
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CHAPTER III 
HYPOTHESIS 
It is becoming increasingly evident that smaller oligomeric forms (~ 2-50mers) of 
A  aggregates are the primary toxic species in AD.  Typically, the intermediates formed 
along the pathway towards fibrils have been considered as oligomers (Figure 4).  
However, it has also become evident over the years that A  can adopt multiple pathways 
of aggregation.
41, 46, 75
  More importantly, exclusive oligomers can be generated via such 
alternate, ‘off-pathways’, which are distinct from the on-pathway of fibril formation.38, 41, 
46, 75
  As described in the previous chapter I, it is also well known that environmental 
factors affect the dynamics of the on- and off-pathways of aggregation, among which 
interfaces formed by lipids are significant and can promote the formation of oligomers at 
the cost of fibrils.
96, 97
  It is important to understand the pathways of A  aggregation 
because if some oligomers are formed as off-pathway products, their half-life could be 
significantly higher than the on-pathway ones, which may result in prolonged toxicity to 
neuronal cells. 
Figure 4. Schematic diagram of A  aggregation indicating on- and off-pathways  
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We hypothesize that alternate pathways of Aβ aggregation induced by fatty acid 
interfaces can generate oligomers with unique conformations, resulting in distinct 
physiochemical and cellular properties. 
Specific Research Objectives 
Objective 1:  To study the effect of various non-esterified fatty acids (NEFAs) on A  
aggregation and pathways. 
We will explore whether anionic interfaces generated by these NEFAs (C9-C12) 
can form off-pathway oligomers in vitro using biophysical techniques.  
Objective 2: To isolate and explore the physiochemical properties off-pathway Aβ 
oligomers generated in the presence of NEFAs. 
We will isolate oligomers generated in the presence of NEFAs.  Their 
physiochemical properties will then be explored using biophysical methods and 
compared with known oligomers like ADDLs, Aβ globulomers, prefibrillar oligomers 
(PFOs) and fibrillar oligomers (FOs).  
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CHAPTER IV 
RESULTS & DISCUSSION 
The Effect of NEFAs on Aβ Aggregation 
Based on the existing literature on interfacial aggregation of Aβ as described in 
the previous sections, we hypothesize that NEFAs will uniquely affect Aβ aggregation in 
a concentration-dependant manner.   
Determination of the Critical Micelle Concentrations (CMC) of Saturated NEFAs 
The CMCs of standard NEFAs are well known, but it is not a fix value and can be 
greatly affected by the presence of slats and other ions in solution. In order  to ensure that 
the buffer and salt conditions  (20 mM Tris pH 8.0 and 50 mM NaCl) used for Aβ 
aggregation do not interfere with their physical properties, e.g. micelle formation, 
therefore their CMC values were experimentally determined based on a previously 
published report using N-phenyl-1- naphthylamine (NPN) as a fluorescent probe.
98
   
NEFAs with varying carbon chain length of C9 (pelargonic acid), C10 (capric acid), C11 
(undecylic acid) and C12 (lauric acid) were used in our study (Figure 5A).  The 
normalized fluorescence titration curves for varying concentrations of NEFAs are shown 
in Figure 5B.  The first inflection point that occurred upon increasing the fatty acid 
concentration was considered to be the CMC, as reported.  The CMC values determined 
from Figure 5B were plotted as a function of carbon chain lengths, which showed an 
expected linear relationship (Figure 5C). 
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Effect of NEFAs on Aβ42 Aggregation 
Previously, it has been shown that varying concentrations of SDS can affect the 
rate of Aβ aggregation kinetics and can also dictate the aggregation pathway 75.  Based on 
this and other similar reports, Aβ42 was incubated with three specific concentrations of 
NEFAs: a) below, b) near and c) above CMC.  
 
Figure 5. Determination of Critical Micelle Concentrations (CMC). A) NEFAs 
used in this study: ‘n’ represents the carbon chain length; B) N-phenyl-1- 
naphthylamine (NPN) fluorescence response curves for various fatty acids: C9 
(), C10 (), C11 () & C12 (); C) CMC of various fatty acids plotted as a 
function of carbon chain length. 
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Aggregation kinetics of Aβ42 co-incubated with each NEFA was monitored using 
ThT fluorescence as shown in Figure 6A-D.  Aβ42 peptide (25 μM), buffered in 10mM 
Tris, 50 mM NaCl, pH 8.0 was incubated in the absence of NEFAs at 37 
o
C as a control 
and showed a signature sigmoidal curve of aggregation with a lag time of ~ 58 hours 
(Figure 6A-D,control). 
The concentrations well below CMC for fatty acids (20 mM C9, 10 mM C10, 2 
mM C11 and 2 mM C12;  in Figure 6A-D) displayed aggregation profiles similar to 
that of the control.  Co-incubation in the presence of NEFAs near their respective CMCs 
(100 mM C9; 50 mM C10; 20 mM C11 and 5 mM C12;  in Figures 6A-D) showed an 
augmented rate of aggregation based on ThT fluorescence signals, without significant 
lag-times as observed in the control sample.  On the contrary, Aβ incubations at 
concentrations above CMC (300 mM C9, 150 mM C10, 75 mM C11 and 20 mM C12;  
in Figures 6A-D) seemed to inhibit the rate of aggregation.  The data were appropriately 
blank corrected. 
We also removed small aliquots of samples after 130 hours of incubation from the 
above reactions and subjected them to SDS-PAGE analysis and immunoblotting using 
the Ab9 monoclonal antibody, which is specific to the Aβ42 N-terminus (Figure 6E).  
The control Aβ42 incubated alone showed the presence of monomeric and fibrillar (F) 
bands, which correlates with the observed ThT fluorescence (Figure 6E; lane 2).  
Likewise, fatty acid concentrations well below CMC showed an identical banding pattern 
to the control sample (Figure 6E; lanes 3, 6, 9 & 12).  For near CMC fatty acid 
concentrations, a predominant band around 50-80 kDa corresponding to a 12-18mer 
species (lanes 4, 7, 10 & 13; indicated by triple arrows) was observed, along with 
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monomeric and fibrillar (F) bands. A faint band around 20 kDa (5mers) was also 
observed, indicated by double arrows (Figure 6E).  On the other hand, incubations above 
CMC mainly showed the presence of a 16-20 kDa band corresponding to a 4-5mer 
species (lanes 5, 8, 11 & 14).  In addition, a monomeric band was also observed, which 
could be due to partial dissolution of aggregates by the high SDS concentration during 
electrophoresis.  Similarly, the appearance of the faint 20 kDa band in the case of near 
CMC incubations could also be due to partial dissociation of 12-18mers. 
We have termed these oligomers as ‘Large Fatty Acid-derived Oligomers 
(LFAOs)’ for 12-18mers and ‘Small Fatty Acid-derived Oligomers (SFAOs)’ for 4-
5mers, and they will be henceforth called as such. The SDS-PAGE electrophoresis 
analyses were carried out on 12% bis-Tris acrylamide gels using Laemmli buffer.  In 
sum, it was evident from the data that concentrations near and above CMC, which 
showed completely different Aβ42 aggregation patterns as compared to the control, 
predominantly form two distinct oligomeric species: LFAOs and SFAOs, respectively.   
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Figure 6. Dependence of Aβ42 Aggregation on Fatty Acid Concentration Monitored 
by ThT Fluorescence.  Monomeric Aβ42 (25 μM) was incubated at 37 C in buffer 
alone () or with varying concentrations of fatty acids C9 (A), C10 (B), C11 (C) and 
C12 (D), which are either above (▽), below () or around () their respective 
CMCs.  The data was fit with Eq 1; E) Western blots of Aβ42 with varying 
concentrations of fatty acids after 128 hours of incubation probed using the Ab9 
monoclonal antibody.  The double arrow indicates SFAOs while the triple arrow 
indicates LFAOs of A 42. 
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Biophysical Differences Between LFAOs and SFAOs 
Next, we studied the morphological and stability differences/similarities between 
LFAOs and SFAOs using biophysical techniques. 
Morphology 
Atomic force microscopy (AFM) was used to observe the morphologies of Aβ42 
aggregates generated in the presence of NEFAs near and above CMCs.  The AFM work 
was done collaboratively in Dr. Morgan’s research group at USM.  Small aliquots of 
sample after 240 hours of the reactions in Figure 6, both near and above CMCs of fatty 
acids, were removed and deposited on a freshly cleaved mica surface, and AFM images 
were taken using the tapping mode (Figure 7).  As expected, the control sample in the 
absence of fatty acid showed large fibrillar structures throughout the mica surface (Figure 
7A).  The measured averaged cross-sectional height was 6.1± 0.8nm for control fibrils, 
whereas distinct morphological differences were observed between near- and above-
CMCs samples.  A mixture of fibrillar and smaller rounded/oblong features were 
observed for near-CMCs samples (Figure 7B, D, F, & H).  The measured averaged cross-
sectional heights were 5.6±1.3 nm and 7.9±2.9 nm for smaller rounded/oblong and 
fibrillar features, respectively.  In contrast, Aβ samples incubated with NEFAs above 
CMCs showed only the presence of smaller round/oblong features with a measured 
averaged cross-sectional height of 6.7±1.0 nm (Figure 7C, E, G & I), and no fibrils were 
present in the sample.  Overall, AFM data suggest that the LFAO and fibril structures 
formed in near-CMCs samples are morphologically different from SFAOs, 
predominantly formed in above-CMCs samples. 
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Figure 7. Morphological Differences between SFAOs and LFAOs.  Aliquots of the 
samples from Figure 6 were probed to see the morphologies of A 42 aggregates 
generated in the presence of varying concentrations of fatty acids either near or 
above CMC by atomic force microscopy (AFM).  A) control; B & C) 100 & 300 
mM C9; D & E) 50 & 150 mM C10; F & G) 20 & 75 mM C11; H & I) 5 & 20 mM 
C12.  Each square represents 5 x 5 m.  The inset shows a different field with 
dimensions of 1 x 1 m. 
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Seeding Experiments Suggests LFAOs and SFAOs may be Structurally Different 
It is evident from ThT fluorescence experiments, immunoblotting, and AFM data 
that LFAOs and SFAOs may have subtle differences in their structures.  As discussed 
earlier, the lag-time in aggregation can be eliminated by adding preformed ‘seeds’ to 
monomeric Aβ.14  The structure and morphology of the seeded aggregates depend on the 
nature of seed itself. 
99
  This means if the added ‘seed’ has structural similarity with the 
growing fibrils; the seed will promote and accelerate the formation of the ‘on-pathway’ 
fibrils.  In previously published reports, seeding experiments were performed to 
indirectly assess the structural assembly of the seed, and to understand the pathways of 
aggregation.
99-102
  In our experiments, Aβ42 monomers were incubated with NEFAs to 
generate LFAOs and SFAOs as described above.  After 48 hours 10% (v/v) of the 
reaction mixture was removed and added to the freshly purified, seed-free monomeric 
Aβ42 at 37 C.  Small aliquots of the incubated samples were electrophoresed on 12 % 
 
Figure 8: Immunoblot of SFAOs and LFAOs.  Western blots of A 42 with fatty 
acids above and near the CMC, after 48 hours of incubation.  The double arrow 
indicates SFAOs, while the triple arrow indicates LFAOs.  Monomeric A 42 and 
control (in the absence of fatty acids) are represented by M and C, respectively. 
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acrylamide gels to ascertain the formation of LFAOs and SFAOs after 48 hours (Figure 
8A). 
We also compared this to a 4-12% gradient NuPage gel (Invitrogen Inc) to get 
better separation and resolution of monomeric and dimeric bands as compared to the 12% 
gel (Figure 8B).  No bands were observed between monomer and SFAOs for all the 
samples, confirming that there were no dimer bands in the incubated samples.  A positive 
control sample containing Aβ42 and 2 mM SDS, which forms 2-4mers, was also included 
in the gel (Figure 8B, lane 5).
75
  
These seeding reactions were also monitored by ThT fluorescence for 100 hours 
(Figure 9).  The 10% (v/v) fatty acid solution was used alone as a control.  The 10% (v/v) 
seeds from the control Aβ42 sample alone showed marginal seeding efficiency as 
indicated by a slight increase in the rate of aggregation for the seeded sample (Figure 
9A).  The sample containing LFAOs as seeds rapidly augmented the rate of Aβ42 
aggregation as compared to unseeded control samples (Figure 9B, D, F, & H).  In 
contrast, the sample containing SFAOs as seed followed a similar aggregation pattern to 
unseeded control samples (Figure 9C, E, G, & I).  
The results indicate that LFAOs may be structurally compatible with ‘on-
pathway’ fibrils, thereby rapidly promoting their formation by acting as a seed, whereas 
SFAOs could be structurally dissimilar to LFAOs and fibrils and therefore unable to seed 
the aggregation of Aβ42.  In other words, one could say that the LFAOs and SFAOs may 
be subtly dissimilar in structure, which causes differences in their seeding behavior. 
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Figure 9. Seeding Experiments with SFAOs and LFAOs.  (A-I) A  monomer (25 
μM) was incubated alone or with 10% (v/v) seed of 48-hour incubated samples of 
Figure 8A at 37
o 
C and monitored by ThT fluorescence.  The figures on the left and 
right panel represent seeding with LFAOs and SFAOs, respectively.  The unseeded 
control () is same reaction as the seeded () one, except it lacks seed. 
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LFAOs and SFAOs have Varying Thermodynamic Stability 
Based on the seeding efficiency of LFAOs and SFAOs as observed from the 
above experiment, it was evident that the oligomers may have different structural 
assemblies.  In order to further confirm this, differences in their equilibrium stabilities 
was compared by using temporal denaturation melting curves of near- and above-CMC 
fatty acids incubated with Aβ42, using GnHCl as a denaturant.  In this experiment, 
samples containing LFAOs and SFAOs were titrated with increasing concentration of 
GnHCl and changes in intrinsic tyrosine fluorescence were monitored at 276 nm (Figure 
10).  No melting changes were observed upon addition of GnHCl for control monomeric 
Aβ42, as expected for a natively unstructured protein (, Figure 10A, B & C).  On the 
other hand, LFAOs and SFAOs formed in near- and above-CMCs, respectively, showed a 
significant shift in fluorescence intensity with low GnHCl concentrations followed by a 
gradual decrease in intensity to almost the level of control monomeric Aβ42 with 
increasing GnHCl concentrations ( & ; Figure 10).  Only the melting curves for C10, 
C11 & C12 were shown in Figure 10 because the first four or five data points collected 
for C9 at low concentrations of GnHCl were inconsistent, especially due to high 
concentration of fatty acids.  It is possible that initial addition of low concentration of 
GnHCl can cause precipitation of fatty acids, resulting in erratic data points followed by 
stabilization of the solution at higher concentrations.  Because of this, it was very hard to 
collect reliable data for C9 near- and above-CMCs samples.  It was observed that LFAOs 
melted earlier than SFAOs in case of all three fatty acids C10, C11 & C12 (Figure 10).  
The apparent melting denaturant concentration (CM) values for LFAOs (; Figure 10) 
were 1.94 ± 0.05, 0.87 ± 0.1 and 1.86 ± 0.04 M for C10, C11 and C12, respectively. In 
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contrast, SFAOs required a higher concentration of GnHCl for melting. The CM values for 
SFAOs (; Figure 10) were 2.55 ± 0.03, 2.38 ± 0.06 and 3.83 ± 0.09 M for C10, C11 and 
C12, respectively. 
Figure 10. Thermodynamic Stabilities of SFAOs and LFAOs determined by 
GnHCl Denaturation Experiments.  A 42 (25 M) was incubated alone () or with 
NEFAs C10 (A), C11 (B) and C12 (C) in similar conditions as Figure 11 at 
concentrations near () and above () their CMCs.  Three scans were averaged 
and the areas under the peaks were normalized and plotted against GnHCl 
concentrations.  The data was fit using Boltzman’s sigmoidal fit (Eq. 2) by Origin 
7.0.  Three data sets were averaged.    
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  To rule out the possibility of a shielding effect by the high concentration of fatty 
acids required for SFAO generation, a negative control experiment with a 7 kDa non-
aggregating protein called human granulin A (Grn-A), comparable in size to Aβ42, was 
performed in similar manner (data not shown).
103
  The data obtained showed that there is 
a slight shielding effect in higher fatty acid concentrations as compared to lower 
concentrations, and this difference in melting concentrations was very low compared to 
the difference between LFAOs and SFAOs.  It was also interesting to observe that the 
SFAOs formed in C12 fatty acid appeared to be more stable than SFAOs of C10 & C11 
fatty acids.  Overall, the data showed that SFAOs are more stable than LFAOs and 
complement the previous data, which indicated that these two oligomeric species may be 
structurally different. 
Discussion 
It is well known that interfaces, whether physiological or non-physiological, can 
have profound effect on Aβ aggregation.  The interaction of Aβ42 with medium-chain 
saturated NEFAs has provided useful insights about the phenomenon of interfacial 
aggregation.  The data presented here clearly indicate that different concentrations of 
fatty acids can dictate multiple pathways of Aβ aggregation.  Interestingly, the pathway 
adopted by Aβ mainly depends on the nature of interface (non-micellar/micellar) 
generated by specific concentrations of NEFAs, not by the type of fatty acid used.  In 
other words, the same type of LFAOs or SFAOs were generated by near and above CMC 
fatty acids irrespective of the carbon chain length, indicating that concentration relative to 
CMC plays a crucial role in dictating pathways.  This is evident from the observation that 
a similar concentration of 20 mM has completely different Aβ aggregation profiles in the 
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cases of C9, C11 and C12, but the Aβ:NEFA ratio was constant in all cases (Figure 6).  
20 mM concentration (well below CMC) in the case of C9 does not affect aggregation, 
but on the other hand the same 20 mM concentration forms LFAOs (near CMC) and 
SFAOs (above CMC) in the cases of C11 and C12, respectively (Figure 6E).  Moreover, 
an increase in the formation of fibrils was observed at a fatty acid concentration near the 
CMC, which forms LFAOs, when Aβ:NEFA ratios were increased (Figure 11).  
Similarly, when Aβ:NEFA ratios for fatty acid concentrations greater than CMC, which 
form SFAOs, were increased, the formation of LFAOs was observed (Figure 11), 
indicating that apart from CMC, ratios of Aβ:NEFA are also crucial in dictating the 
pathways and nature of oligomers formed. 
LFAOs and SFAOs Are Kinetically Trapped Off-pathway Intermediates 
LFAOs were generated within 24-48 hours of incubation of Aβ42 with near CMC 
concentration of fatty acids at 37 C and remained stable for at least 10 days.  The 
increased ThT fluorescence observed with LFAOs causes doubt as to whether it arises 
 
Figure 11. Incubation of 5 & 20 mM C12 with Varying  Concentrations of  Aβ42 
; lanes (1-4) 5 mM C12 with 12.5 μM , 25 μM , 50 μM , 75 μM Aβ42  
respectively ; lanes (5-8)  20 mM C12 with 12.5 μM , 25 μM , 50 μM , 75 μM 
Aβ42 respectively. 
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from LFAOs or some fibrils that may be present (Figure 7).  To complicate the issue, we 
know that LFAOs are structurally similar to fibrils, as they were able to seed Aβ42 fibril 
formation (Figure 9).  
However, two separate experiments indicated that they might be off-pathway 
intermediates.  First, they remained stable even after ~500 hours of incubation, which is 
unlikely for on-pathway intermediates (Figure 12A).  Secondly, known fibril inhibitors 
like Congo Red and Rifampicin failed to inhibit the formation of LFAOs (Figure 12C).
41, 
46
  Conversely, seeding experiments suggested that LFAOs may have structural 
similarities with on-pathway fibrils because of their seeding efficiency (Figure 9), and 
also NEFA free, isolated LFAOs slowly converted to fibrils after ~500 hours incubation 
at 37
o
C (Figure 12B).  Together, the data suggested that LFAOs might be kinetically 
trapped as off-pathway oligomers in the presence of NEFAs, but after isolation (removal 
of fatty acid, elaborated in the next section) they slowly convert into on-pathway fibrils 
by associating with themselves (Figure 12).  But since the conversion to fibrils of LFAOs 
free of associated NEFAs occurs at a very slow rate, it is likely that LFAOs are 
kinetically trapped off-pathway oligomers.  
On the contrary, SFAOs formed above CMC concentration clearly indicated that 
they are off-pathway species.  They failed to show any increase in ThT fluorescence and 
also completely failed to convert to fibrils even after ~500 hours of incubation (Figure 
12C).  Moreover, SFAO samples were fairly homogenous and without any fibrils as 
observed by AFM images (Figure 6E and 7).  And no increase in the rate of aggregation 
was observed on seeding; indicating that they might be structurally incompatible with on-
pathway fibrils, which further complements the finding that they are off-pathway species.  
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Unfortunately, all attempts to isolate SFAOs using SEC like LFAOs were unsuccessful; 
therefore the seeding efficiency of isolated SFAOs was not evaluated. 
 
 
 
Figure 12. Oligomeric LFAOs as well as SFAOs are Formed Along ‘Off-pathway’. 
All samples were electrophoresed on 4-12 % NuPage gels with MES running buffer. 
A) Immunoblots of incubations of buffered 25 μM Aβ42 with 5 and 20 mM C12 for 
~500 hours at 37 C similar to Figure 11.  Double and triple arrowheads indicate 
SFAOs and LFAOs respectively; B) Immunoblots of SEC fractionated LFAOs (9 
μM) of Aβ42 (Figure 20) in 20 mM Tris-HCl, 50 mM NaCl, pH 8.0 incubated at 
37 C for the indicated times; C) Effect of fibril inhibitors like Congo red (CR) & 
Rifampicin (Rfn) on Aβ42 oligomer formation.  Lanes 1-5 show 25 μM Aβ42 
incubations with 5 mM C12: lane 1 – with no inhibitors, lane 2 and 3 – with 6- and 8-
fold molar excess of CR, lane 4 and 5 – with 6- and 8-fold molar excess of Rfn. 
Lanes 6-10 show similar 25 μM Aβ42 incubations with 20 mM C12: lane 6 – with no 
inhibitors, lane 7 and 8 – with 6- and 8-fold molar excess of CR, lane 9 and 10 – with 
6- and 8-fold molar excess of Rfn.          
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Together, the data suggested that both LFAOs and SFAOs are transiently trapped 
as off-pathway oligomers.  It is also possible that fatty acid might play an important role 
in stabilizing the structure of oligomers, and their removal may have a destabilizing effect 
on oligomers. 
The exact nature of the Aβ-NEFA interaction is unclear at this time.  However, a 
rough model portraying the possible mechanisms of Aβ-NEFA interaction based on the 
above results is shown in Figure 13.  If non-micelle            micelle was assumed to be a 
determined reaction with the equilibrium constant, KD, being equal to the CMC value, 
then it is obvious that above the CMCs, Aβ mainly interacts with the micellar form 
(Figure 13).  Based on our observation of SFAO formation, it seems likely that the 
anionic interface provided by micelles accommodates 4-5 Aβ monomers.  These SFAOs 
seem to be thermodynamically more stable (stabilized by micelles) than LFAOs (Figure 
10).  Interestingly, no effect on Aβ aggregation was shown with non-micellar 
concentrations of NEFA (<<CMC) (Figure 6).  Near the CMC concentration, a dynamic 
equilibrium exists between non-micellar           micelle transitions, which seems to exert a 
unique effect on Aβ aggregation.  Near CMC, no well-defined interface forms, this may 
result in different modes of interaction between Aβ and fatty acids (Figure 13).  In other 
words, LFAOs may be kinetically trapped intermediates along the ‘off-pathway’ as 
compared to thermodynamically stable SFAOs.  
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Figure 13. Schematic Model of Aβ42 Aggregation Pathways in the Presence of NEFAs 
Based on the Data Obtained in the Study. The square brackets indicate isolated 
oligomers while the question marks indicate that these parts were not explored in this 
study. 
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Physiochemical Properties and Self-propagation of LFAOs 
 LFAOs and SFAOs generated in the presence of 5 and 20 mM C12 fatty acid 
respectively were isolated using SEC to further explore their stability in the absence of 
fatty acid, physiochemical properties and prion-type self propagation behavior. 
Isolation of Oligomeric LFAOs and SFAOs 
In order to further characterize these oligomeric species, it was very important to 
isolate them, free of monomers, fibrils and fatty acids.  This will help in understanding 
and exploring the molecular features of these specific oligomeric species and provide 
information about their stability in the absence of fatty acids.  To do so, 50 μM Aβ42 was 
incubated with 5 or 20 mM C12 fatty acid for 48 hours to generate LFAOs and SFAOs 
respectively, as shown in Figure 6E (Chapter IV.1).  After 48 hours, LFAOs (incubation 
with 5 mM C12) were subjected to SEC using a Superdex-75 column (see next 
subsection VII).  The presence of residual NEFAs present, if any, in the isolated LFAO 
fractions was quantified using a free fatty acid assay kit (BioVision Inc., Milpitas,CA) 
method as published previously.
104
  This experiment indicated a negligible amount 
(<0.1%) of NEFA was present in fractions containing isolated LFAOs (Figure 14).  The 
results clearly suggest that LFAOs can maintain their structural integrity even after 
isolation and removal of fatty acids.  Attempts to isolate SFAOs using SEC were 
unsuccessful (data not shown) and hence, were not further pursued. 
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LFAOs are Disperse Oligomers 
The isolation of LFAOs generated in the presence of 5 mM C12 and their 
molecular size distribution were estimated using SEC and analytical ultracentrifugation 
(AUC), respectively.  The Aβ42 was incubated with 5 mM C12 fatty acid at 37 C for 48 
hours to generate LFAOs as described (Figure 6E; Chapter IV.1) and subjected to 
fractionation on a Superdex-75 SEC column (Figure 15A, smooth line).  The samples 
eluted in two major peaks, one between fractions 17 and 20 and the other between 
fractions 22 and 25.  A small extra peak was also observed near the void volume (fraction 
 
Figure 14. Quantitation of NEFA Content in Isolated LFAOs: The amount of 
NEFA associated with LFAOs before and after SEC fractionation was estimated 
using free fatty acid quantification kit.  The experiment was performed as per the 
manufacturer’s instructions.  Briefly, a standard curve was generated by adding 2 μl 
aliquots of a known concentration of palmitic acid to each well containing the 
reaction mixture provided by manufacturer ().  The reactions were monitored 
colorimetrically at 570 nm.  The concentration of NEFA present in 2 μl aliquots of 
LFAOs before (pre SEC; ▲) and after (post SEC; ●) isolation by SEC were 
estimated using standard curve.  Based on this analysis, NEFA concentration before 
SEC was estimated to be 4.5 mM, which is comparable to the 5 mM used.  On the 
other hand, for the isolated LFAO, a negligible amount of NEFA was detectable in 
the sample, suggesting a complete removal of NEFAs from LFAOs upon 
fractionation.   
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16) of the column.  The LFAOs are eluted in the partially included volume fractions 17 
and 18 as compared to monomers, which eluted in fractions 22-25. The SEC profile of 
LFAOs was compared with those of globular protein standards (gel filtration standards, 
Bio-Rad) to estimate the molecular mass of LFAOs based on retention volume (data not 
shown). Based on this analysis, the molecular mass of LFAOs was estimated to be 
between 60 and 200 kDa. Additionally, Aβ42 protofibrils (PFs), which have a molecular 
mass >200 kDa were also subjected to fractionation under similar condition as LFAOs.
105, 
106
   The SEC profile of PF sample mainly showed two elution peaks, one at the void 
volume at fraction 15 (Vo; Figure 15A, black arrow) for PFs and second for monomers at 
fractions 22-25 (Figure 15A, dashed line). The SEC fractionation of PFs further 
supplemented our observation with globular protein standards that molecular mass of 
LFAOs is between 60 and 200 kDa. The AFM of the isolated LFAOs mainly showed a 
bimodal distribution of non-fibrillar punctuate dots like structures with an average height 
ranging from 7-10 and 16-19 nm (Figure 15A, inset).  
The sedimentation velocity experiments in an analytical ultracentrifuge were 
performed to estimate the molecular size distribution of LFAOs. The AUC experiments 
were done in our collaborators Dr. John Correia lab at UMMC.  For these experiments, 
FITC-Aβ42 was introduced into LFAOs assembly (as described in the Materials and 
Methods, Chapter II) to facilitate monitoring by fluorescence detection system (FDS). 
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In AUC, the rate of sedimentation of macromolecules was monitored in the 
presence of centrifugal force, which allows the determination of their hydrodynamic 
radius and thermodynamic properties in solutions.
107
  AUC is the method of choice to 
determine the exact molecular mass of proteins and their complexes and also to study 
 
Figure 15.  Isolation and Characterization of LFAOs.  A) The SEC fractionation of 
LFAOs using a Superdex-75 column in 20 mM Tris pH 8.0 at room temperature with a 
flow rate of 0.5 mL/min and a fraction size of 0.5 mL.  As a comparison, a sample of 
protofibrils (PFs) of Aβ42 was as also fractionated.  Vo indicates the void volume 
based on globular protein standards.  (Inset): AFM image of fractionated LFAOs.  
Scale bar represents 2.5 μm.  B) Normalized c(S) distribution profile generated from a 
sedimentation velocity experiment performed at 50,000 x g.  (Inset): Immunoblot of 
LFAOs before and after fractionation.  Single arrow indicates 50-70 kDa bands while 
double arrow indicates 80-110 kDa bands. 
 
52 
 
 
protein self-assembly and heterogeneous interactions like protein-protein, protein-DNA 
and protein-small agents.
107
  
Labeling with FITC reduces the amount of sample needed and facilitates 
detection at very low concentrations.  The c(S) sedimentation coefficient distribution 
profile, which helps to model the hydrodynamic radii of proteins and their complexes in 
solution, of  LFAOs before and after fractionation was analyzed to observe any size 
differences (Figure 15B).  The Aβ42 sample incubated with 5 mM C12 before 
fractionation when subjected to AUC showed a distribution of multiple peaks with a 
sharp peak centered on 4 S and a more disperse peak between 6 and 12 S with a 
additional peak at ~ 1 S (Figure 15B, dotted lines).  The 1 S peak corresponds to 
monomeric Aβ42 as determined by running a control sample (Figure 16A), and SEC 
fractionated LFAOs (fraction 17) showed an almost identical AUC profile as the 
unfractionated sample, with a main peak centered at 5 S and a second disperse peak 
between 7 S and 12 S, along with a monomeric 1 S peak (Figure 15B, smooth lines).  The 
LFAOs showed a similar peak distribution even after 10- & 50-fold dilutions (data not 
shown).  A relative decrease in the amount of monomers was also observed after SEC: 
52.3% and 14.3% monomers before and after fractionation, respectively.  The Aβ42 
fibrils were also analyzed by AUC to compare with LFAOs; they on the contrary showed 
a heterogeneous mixture of large species between 40 and 200 S (Figure 16B).  The 
immunoblots of the LFAO sample both before and after SEC primarily showed a disperse 
band between 56 and 110 kDa with two distinct band distributions; one is around 56-70 
kDa and other is centered at 80-110 kDa (Figure 15B, inset).  The immunoblot band 
distribution further complements the bimodal distribution observed in AFM and AUC 
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data.  Together, the data suggest that LFAOs are not discrete, but a disperse mixture of 
oligomeric species.    
LFAOs are Self-propagating Oligomers 
Prion proteins are well known to undergo corruptive template assisted self 
replication by converting normal prion proteins (PrP
C 
) to misfolded (PrP
Sc
)form.
77
  
Recent studies have shown that a prion-type propagation mechanism is also involved in 
the pathogenesis of other neurodegenerative diseases like PD, FTLD and ALS.
80-84
  But 
prion type self-propagation is a relatively new and unexplored area in the AD field, and 
so far only two oligomeric species of Aβ, prefibrillar (PFOs) and fibrillar oligomers 
(FOs), have been shown to possess a self-propagating property upon interaction with 
monomeric Aβ.85, 86  Therefore, we want to explore whether LFAOs can self-propagate 
upon monomer addition. 
For this experiment, 20 μM freshly purified, aggregate-free, monomeric Aβ42 
was incubated with 0.4 μM (2% molar ratio) isolated LFAOs as a seed at ambient 
temperature, and the reaction’s progression was monitored with ThT, immunoblotting 
 
Figure 16. AUC of Monomer and Fibril.  A c(S) distribution profile generated from 
sedimentation velocity experiments for Aβ42 monomers (A) and fibrils (B). 
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and SEC.  Small aliquots of samples were removed at 24, 48 & 72 hours and subjected to 
SDS-PAGE and immunoblotting.  The amount of sample loaded in each lane was kept 
constant at 28 ng based on the initial concentration of LFAOs seed (Figure 17A), for the 
approximate quantification of the blots.  The immunoblot clearly showed a more intense 
LFAO band centered around 100 kDa within 24 hours compared to the 0 hour sample 
(lane 3).  The 100 kDa band represents the higher molecular weight species of LFAO 
(80-110 kDa) from the two species observed for isolated LFAOs (lane C), and the lower 
molecular weight species (~56-70 kDa) was completely absent (Figure 17A; 24 hours).  
A progressive increase in the 100 kDa band intensity was observed after 48 and 72 hours, 
along with a continuous decrease in the monomer band intensity, indicating that 
monomers were being converted into more LFAOs (Figure 17A; 48 and 72 hours).  
Moreover, a large molecular weight species was also observed at the top of gel after 72 
hours (lane T; 72 h), which was absent in the supernatant sample loaded on the gel after 
centrifuging the sample for 20 minutes at 19,000 x g, suggesting the formation of fibrils.  
Some degree of fibril formation was expected because it is likely that besides monomer-
LFAO interactions, monomer-monomer interactions occur in parallel, leading to on-
pathway fibrils.  The propagation reaction was also monitored by ThT fluorescence 
(Figure 17C).  The Aβ42 seeded with 2% LFAOs (Figure 17C,○) showed a lag phase of 
~72 hours as compared to control ~84 hours (Figure 17C, ■), indicating a relatively 
insignificant amount of seeding.  But a significant amount of seeding (reduction in lag 
phase) was observed with 20% seed in our previous experiment (data not shown).  A 
significant amount of LFAOs was also observed in the seeded sample immunoblots run 
during the lag phase (24, 48 and 72 hours), which was not seen in the control (Figure 
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17A).  This clearly suggests that the propagation of LFAOs mainly occurred during the 
lag phase.  Notably, immunoblots showed that the propagation reaction occurring upon 
seeding with LFAOs only leads to the formation of 80-110 kDa oligomeric species at the 
expense of the 56-70 kDa species observed in LFAO seeds.  
In order to confirm that propagation leads to a quantitative increase in LFAOs that 
would occur in a self-propagating event, SEC was used.  Aβ42 (50 μM) was seeded with 
2% LFAOs (1 μM) and incubated for 72 hours.  Immunoblots after 24, 48 and 72 hours 
of incubation confirmed propagation process as shown in Figure 17A.  The samples were 
subjected to SEC fractionation after the indicated times.  Fractions 16-19 showed the 
presence of propagated LFAOs on immunoblots (Figure 17B).  A ~4-fold increase in the 
amount of LFAOs was observed in SEC, as shown by absorbance in comparison with 
non-seeded sample fractions after 72 hours (Figure 17D).  The Far-UV CD of SEC 
fraction 17 at 24, 48 and 72 hours points also showed a progressive increase in β-sheet 
conformation, further complementing the observation of an increase in LFAO amount 
upon seeding (Figure 17E).  The formation of 80-110 kDa species upon seeding that 
seemed to occur at the cost of 56-70 kDa species was confirmed by sedimentation 
velocity analysis before and after 72 hours of propagation cycle at room temperature 
(Figure 17F).  The sample after propagation showed a significant peak shift towards ~80-
110 kDa species (Figure 17F, smooth line), which supported the immunoblot data (Figure 
17A) and consolidated the observation that the high molecular weight ~80-110 KDa 
species was predominantly formed upon propagation.  A slight decrease in the amount of 
monomer ~6 % was also observed in the seeded sample AUC data (Figure 17F), further 
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strengthening the observation that propagation leads to quantitative conversion of 
monomer to LFAOs. 
 
Figure 17. LFAOs Propagate upon Interacting with Monomers.  A) Immunoblot of 20 μM 
Aβ42 incubated with 0.4 μM LFAO (2 % seed) for 72 hours at room temperature before and 
after SEC.  C represents LFAO control (338 ng).  Lanes 1 and 2 are Aβ42 control after 72 
hours in the absence of LFAO seed and LFAO alone (28 ng), respectively.  Lane 3 is an 
aliquot of 20 μM Aβ42 seeded with 0.4 μM LFAO immediately after incubation (0 h).  
Lanes T and S represent the total and supernatant of the sample after centrifugation at 
19,000 x g for 20 min, at the indicated times of incubation.  The volume of sample loaded 
was kept constant to ensure 28 ng of the parent LFAO was maintained.  B) Immunoblot of 
fraction 17, fractionated by SEC after 24, 48 & 72 hours of incubation of the samples in A 
(lanes S).  C) ThT fluorescence data of the seeded reaction.  The arrow indicates the 72 hour 
point to which the seeding reaction was monitored.  D) Fraction 17 of the seeded samples, 
which was fractioned on a Superdex-75 column after 24, 48 & 72 hours along with a control 
sample (no seed) after 72 hours.  E) The corresponding far-UV CD spectra of fraction 17, 
and F) Normalized relative molecular weight distributions, c(M) profiles obtained from 
sedimentation velocity data for control  LFAOs (dotted line) and seeded oligomers (smooth 
line).  (Inset) Expanded region of the c(M) plot indicated in the figure.   
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Morphology of propagating LFAOs 
The morphology of the seeded sample was also monitored using AFM at different 
time points to observe any changes that might occur during propagation (Figure 18).  The 
0 hour sample, i.e. immediately after seeding (Figure 18A & D), showed few spherical, 
small, punctate dots ~8 nm in heights, representing LFAOs.  The 48 hour (Figure 18B & 
E) sample showed a considerable increase in the number of spherical LFAOs along with 
a slight increase in height (~12 nm), and they appear to align in a straight linear line 
(inset).  The sample after 72 hours (Figure 18C & F) showed a further increase in the 
number of spherical dots with similar height profiles (~14 nm), along with a linear 
alignment of the particles (inset) and a few smooth fibrillar structures.  More importantly, 
the linear alignment of these spherical particles gives the overall appearance of 
‘maturing’ PF.  A similar type of linear arrangement was observed previously when Aβ40 
was incubated in the presence of aqueous-organic interface.
93
  Furthermore, AFM data 
complements the immunoblotting and AUC data and suggests that LFAO undergoes 
propagation.  
Incorporation of Monomers into Replicated LFAOs 
N-terminal Dansyl labeled Aβ42 (Dan-Aβ42) was used as a fluorescent probe to 
further ensure that seeding leads to incorporation of monomers into replicated LFAOs 
assembly. 
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A schematic of the reaction of Dan-Aβ42 and LFAOs is shown in Figure 19A, 
indicating that seeding with LFAO should generate replicated oligomers containing 
labeled peptides, which can be easily detected by intrinsic fluorescence.  A seeding 
experiment similar to Figure 17A was performed using 50 μM Dan-Aβ42 and 1 μM 
 
Figure 18. Morphological Changes during LFAO Propagation.  Aliquots of the samples 
from Figure 17A (before SEC) were probed at different time points to see the 
propagation of oligomers after incubating 20 μM Aβ42 with 0.4 μM LFAO (2 % seed) 
for 72 hours at room temperature.  A, B & C, represent AFM images of the seeded 
sample after 0, 48 & 72 hours, respectively (z scale, 0-0.8 V).  D, E, and F represent the 
corresponding height data from A, B & C, respectively (z scale, 0-40 nm).  The white 
scale bar represents 2.5 μm, and the inset shows a field of dimensions 1 x 1 μm 
surrounding the particles indicated with arrows.  The white boxes in D-F indicate the 
particles for which the height analyses were conducted. Height profiles were extracted 
from the flattened height data and can be seen from the z direction in the height images 
and from the x, y direction below each image.  These height profiles demonstrate how 
approximate feature heights were determined for each sample.  The determined feature 
heights were confirmed via particle analysis (Nanoscope version 5.30 r2 image analysis 
software), shown at the bottom as a secondary technique to increase confidence in 
reported values.   
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LFAOs for 72 hours at room temperature.  After 72 hours, the seeded sample was 
centrifuged at 19,000 x g to remove any fibrils, and the supernatant was subjected to SEC 
fractionation and immunoblotting (Figure 19B & C).  The SEC profile for the isolation of 
propagated LFAOs was exactly comparable to the isolation profile in Figure 17D.  The 
immunoblot also clearly showed a significant increase in the amount of LFAOs after 72 
hours as compared to 0 hour (Figure 19C, lanes 4, 5, & 6).  The SEC fractionated sample 
(fractions 17 & 18) also showed the presence of replicated LFAOs in immunoblot (Figure 
19C, lanes 8 & 9), whereas monomers were fractionated in the inclusion volume peak at 
fraction 24 (Figure 19C, lanes 10).  The fluorescence spectra of fractions 17 & 18 were 
collected by exciting the sample at 350 nm while monitoring Dan-Aβ42 emission at 450 
nm (Figure 19D).  Importantly, both fractions showed dansyl emission at 450 nm, 
indicating that Dan-Aβ42 monomers were incorporated into the propagated LFAO 
assembly upon seeding, providing an unambiguous confirmation for the replication 
mechanism.  In sum, the collective data suggest that LFAOs are self-propagating strains 
of Aβ oligomers.    
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Figure 19. Incorporation of Dan-Aβ42 Monomer into Replicated Oligomers after 
Seeding.  A) Schematic for incorporation of Dan-Aβ42 into propagated LFAOs after 
seeding for 72 hours.  B) 20 μM Dan-Aβ42 incubated with 0.4 μM LFAO (2% seed) 
for 72 hours at room temperature.  The seeded sample was fractioned on a Superdex-
75 SEC after 72 hours; Inset – immunoblot showing the comparison of seeded 
sample before and after SEC.  C represents control LFAO (338 ng).  Lane 1 shows 
Dan-Aβ42 control after 72 hours.  Lane 2 shows an aliquot of the sample after 0 hour 
(total).  Lane 3 shows the incubation after 72 hours.  Lanes 4 and 5 show fractionated 
samples, fractions 17 & 18, respectively, after 72 hours. C) Fractionated sample, 
fractions 17 & 18 showing the Dan-Aβ42 emission at 450 nm upon exciting at 350 
nm with a band width of 20 nm (10/10).  
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LFAOs Form Non-fibrillar, Diffuse Aggregates in Aqueous-Organic Phase Interfaces 
buffer-hexane and buffer-chloroform experiments. Interfaces are well known to affect Aβ 
aggregation, especially aqueous-organic phases.
47
  It has been recently shown that 
prefibrillar oligomers (PFOs) form distinct pore like structures called annular protofibrils 
(APFs) upon interaction with water-hexane interfaces, which remain stable for long 
periods of time without forming fibrils.
47
  It is believed that the formation of this 
ring/pore like structures is one of the mechanisms by which oligomers exert their toxicity.  
The effect of aqueous-organic phase interfaces on LFAOs was explored to observe 
whether they could form any non-fibrillar off-pathway aggregates like APFs.  Two 
interfacial systems were used for these experiments: hexane-water (as used previously for 
PFOs) and chloroform-water.  For this experiment, a protocol previously published for 
PFOs  was followed, and based on that protocol, freshly isolated 2 μM LFAOs were 
 
Figure 20. LFAO Agitation in Interfacial Environments. A) The increase in size of 
LFAO after agitation with 5% (v/v) hexane or chloroform in buffer followed by 
dialysis for 23 hours was monitored by DLS.  B) Immunoblot of the agitation 
experiments along with monomer controls.   Lane 1 shows control monomer Aβ42; 
lanes 2 and 3 dialyzed 23 hours Aβ42 monomer sample treated with chloroform & 
hexane, respectively.  Lane 4 shows control LFAO; lanes 5 and 6, dialyzed 23 hour 
Aβ42 sample treated with chloroform & hexane, respectively.  The single and double 
arrows indicate 50-70- and 80-110-kDa bands, respectively. 
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mixed and agitated with 5% (v/v) hexane-water on a vortexer for 1 hour.
47
  After 
agitation, the sample was dialyzed at room temperature for 23 hours, followed by DLS 
analysis of the dialyzed sample.  The LFAOs treated in hexane-water prominently 
exhibited the formation of large species with a hydrodynamic radius of ~700 nm (Figure 
20A, gray peak), whereas LFAOs in buffer alone showed a monodisperse peak with a 
~10 nm diameter (Figure 20A, black peak) correlating well with the AFM data (Figure 
15A, inset), which showed an average height range of 7-10 nm.  But an immunoblot of 
the same sample failed to show any large species; instead an unexpected decrease in the 
band intensity was observed (Figure 20B, lane 6).  Interestingly, upon the same 
treatment, Aβ42 monomer showed a high molecular weight species band that failed to 
enter the gel, indicating the formation of fibrils (Figure 20B, lane 3). 
The same experiment was repeated with the chloroform-water system, to see 
whether it was possible to replicate the formation of larger aggregates in other interfaces 
too.  The main advantage of using chloroform as compared to hexane is that it is denser 
than water, and buffers can be easily suspended at the top of the organic layer.  The 2 μM 
LFAOs were mixed, agitated and dialyzed in a similar manner as with hexane and 
monitored by DLS, which showed a polydisperse distribution of species with two peaks: 
~700 and 1000 nm (Figure 20A, light gray peak).  The immunoblot of the dialyzed 
sample showed a significant shift towards a higher molecular weight band, further 
complementing the DLS data (Figure 20B, lane 5).  In contrast, upon the same treatment, 
Aβ42 monomer again showed the formation of a very large molecular weight species that 
failed to enter the gel (Figure 20B, lane 2).  
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morphology of the aggregates formed after chloroform and hexane treatment. The AFM 
image of the LFAO treated with hexane-water interface showed the presence of very 
large spheroidal aggregates with an average height of ~33 nm (Figure 21 A).  The 
spheroidal aggregates were almost 3-4 times larger than individual LFAOs in apparent 
diameter and are believed to result from association of LFAOs (Figure 21A).  In contrast, 
 Aβ42 monomer treated with hexane showed the presence of fibrillar structures (Figure 
21B). It is important to point out that LFAOs do not form any ring- or pore-like structure 
like PFOs on hexane treatment, indicating that the assembly of  different soluble 
oligomers can vary depending upon their molecular organization.
47
  LFAOs treated with 
chloroform also showed the presence of large aggregates with an average height of ~21 
nm (Figure 21C).  More importantly, Aβ42 monomer treated with chloroform does not 
show any large fibrillar structures (Figure 21D), as expected based on the immunoblot 
data that clearly indicate the presence of a high molecular weight band at the top of the 
gel (Figure 20B, lane 3).  It is possible that dilution during AFM sample preparation 
might have caused the disaggregation of unstable aggregates formed in chloroform 
interfaces.  This observation was similar to the report published previously for Aβ40, in 
which unstable aggregates get completely disaggregated upon dilution.
52
  Collectively, 
DLS and AFM data indicate that LFAOs, upon treatment with interfaces, also form large, 
non-fibrillar, disperse aggregates with completely different morphology from PFOs and 
that these aggregates may not be the intermediates of the fibril formation on-pathway. 
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Figure 21. Morphology of Aggregates Formed after Treatment with Chloroform and 
Hexane.  A & B) AFM images of LFAO and monomer Aβ42 control, respectively, 
agitated with hexane.  A) LFAOs show the presence of small globular aggregates and 
large clumps of aggregates.  B) Control monomers treated with hexane show the 
presence of fibrils.  C & D) AFM images of LFAO and monomer Aβ42 control, 
respectively, agitated with chloroform.  C) LFAOs show the presence of several large 
clumps of aggregates.  D) Control monomers treated with chloroform failed to show the 
presence of any aggregates.  The height images are presented here. The white scale bar 
represents 2.5 μm, and the inset shows a field of dimensions 1 x 1 μm surrounding the 
particles indicated in the box.  The z scale for all the images is 0-40 nm.  These height 
profiles demonstrate how approximate feature heights were determined for each sample.  
The determined feature heights were confirmed via particle analysis (Nanoscope version 
5.30 r2 image analysis software) shown at the bottom as a secondary technique to 
increase confidence in reported values.   
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 Discussion 
The physiochemical properties of LFAOs that were characterized in this section 
indicate that they are diffuse oligomeric species with a molecular mass ranging from ~56-
110 kDa.  More importantly, immunoblots of isolated LFAOs showed two prominent 
band distributions: a lower molecular weight species band ranging from ~56-70 kDa and 
a high molecular weight species band from ~ 80-110 kDa, corresponding to 12-15mers 
and 18-24mers respectively.  AUC sedimentation velocity data complemented the 
observation that LFAOs are a mixture of oligomeric species, with a heterogeneous peak 
distribution of species corresponding to 5 S, and 7-12 S sedimentation coefficients.  A 
somewhat similar AUC sedimentation velocity profile was recently published by Freir 
and coworkers for ADDLs, indicating that they are also a heterogeneous mixture of 
oligomeric species larger than 90 kDa with a very disperse c(S) distribution ranging from 
10 S to 25 S.
108
  
The most significant and novel property of LFAOs is their self-propagation 
behavior, which can help discover new insights into the pathogenesis of AD. The LFAOs 
can act as seeds to convert non-toxic monomers into toxic, non-fibrillar aggregates, 
displaying a mechanism similar to the ‘template-assisted corruptive’ self-propagation of 
prion proteins (Figure 22A).
77, 109, 110, 111
  It is also possible that the self-propagation of 
LFAOs can act as a trap to direct more monomers away from the fibril formation on-
pathway to a more toxic off-pathway.  Furthermore, propagation leads to a quantitative 
increase in the amounts of LFAOs formed.  The key practical utility of this property is 
that it could be exploited to enhance the amount of endogenous oligomeric seeds by 
amplification to an extent amenable for biophysical characterization, following a method 
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similar to the ‘Protein Misfolding Cyclic Amplification (PMCA)’ method reported 
previously by Soto and co-workers for in vitro prion protein amplification (discussed in 
the next section).
78, 112
   
LFAO: A Novel Off-pathway Self-propagating Intermediate 
All the data presented so far further support our proposed hypothesis that 
oligomers need not be formed along the mandatory fibril formation pathway. LFAOs and 
some other oligomers, like PFOs and FOs, share a common trait in that all of them 
nucleate the formation of oligomers from monomers but not fibrils.
47, 86, 113
  Furthermore, 
the formation of non-fibrillar aggregates upon interactions with monomers and also on 
LFAOs association suggest that the LFAOs are off-pathway intermediates that can also 
compete and recruit more monomers towards this toxic pathway through a unique 
replication mechanism (Figure 22B).  More importantly, the association property of 
LFAOs upon their interfacial interaction can provide valuable insights about the 
mechanism and behavior of endogenous LMW oligomers in the presence of lipid 
interfaces in the physiological environment.  Figure 22B also illustrates the possibility of 
energy minimum states along the aggregation pathway, and it is likely that oligomers get 
trapped in these kinetic minima and thereby promote prolonged toxicity.  Therefore, it is 
possible that these off-pathway routes can recruit more monomers to populate LMW 
oligomers and are more toxic than the nucleation dependent on-pathway.      
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Figure 22: Schematic Diagram Depicting the Generation of ‘Off-pathway’ 
Oligomers and Propagation.  A) The classical fibril formation ‘on-pathway’ of Aβ 
aggregation along with an ‘off-pathway’ is depicted.  The process of replication of 
off-pathway oligomers is shown with dotted lines.  B) An aggregation funnel is 
similar to the protein folding funnel but depicts the aggregation of intrinsically 
disordered proteins such as Aβ towards fibril formation.  This path is considered the 
nucleation-dependant ‘on-pathway’.  The spherical balls represent LMW oligomers.  
However, it is possible that the oligomers adopt a different pathway such that they 
are trapped in local energy minima as ‘off-pathway’ species (oval ball; grey area of 
the funnel).  Such off-pathway species would have a significant energy barrier to 
overcome in order to proceed towards fibrils.  Also, the off-pathway oligomers could 
recruit more monomers and dictate them to adopt such pathways (replication 
process).  This may further increase the energy barrier for such off-pathway 
oligomers to overcome and significantly increase their half-lives in doing so.  
 
 
68 
 
 
Evaluation of Prion-type Behavior of LFAOs 
Encouraged by the prion-like template assisted self-propagation mechanism 
displayed by LFAOs as described in the previous chapter, we wanted to further explore 
whether LFAOs are indeed ‘Prions’.112, 114   The scrapie form of prion, PrPSc (misfolded 
prion protein), is known to undergo a ‘protein misfolding cyclic amplification’ (PMCA) 
process in which small amounts of PrP
Sc
 seeds can be amplified upon making them 
interact with the folded, non-toxic form (PrP
c
) of the protein under controlled conditions 
in vitro.
112, 114
  Such in vitro amplified prions are reported to retain the infectious 
properties of their in vivo counterparts.
115
  The utility of PMCA is that the assay can be 
used as a diagnostic tool for detecting the presence of pathogenic prions by amplifying 
extremely low amounts of in vivo PrP
Sc
 seeds.  The amplification of seeds by the in vitro 
PMCA assay is greatly influenced by the parameters like buffer, temperature, pH, 
sonication and time of incubation etc.
112, 114
  Therefore, for LFAO self propagation, 
optimization of some these crucial parameters is essential to see how, if at all, they can 
affect the propagation efficiency of LFAOs.   
Cyclic Propagation of LFAOs 
In order to assess whether LFAOs could undergo PMCA-type amplification as 
reported for prions, the PMCA protocol developed by Soto and colleagues was followed 
for the amplification of LFAOs, with some modifications.
114-116
  It is interesting to point 
out that LFAOs showed self-propagation behavior at an ambient temperature without 
requiring any special sonication conditions, which is critical for in vitro prion 
amplification.
112, 114
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First, as described in the previous section, LFAOs were subjected to self-
propagation by seeding (2%) 50 μM buffered Aβ42 monomers at room temperature for 
72 hours.  After 72 hours, the incubated sample was centrifuged at 19,000 x g for 20 min 
to remove any fibrils, and the supernatant was subjected to fractionation by SEC using a 
Superdex-75 column (Figure 23A).  This amplification/propagation cycle of LFAO was 
termed as ‘Cycle-1’.  The comparison of SEC profiles of the seed alone (dotted line) and 
seeded sample (black line) are shown in Figure 23A.  The seeded sample showed a ~3.5 
fold increase in the amount of seeds after Cycle-1 as compared to seed alone (Figure 
23D; Cycle-1), consistent with our previous observation (Chapter IV.2).  The 
immunoblot of the aliquots of seeded sample (Figure 23 E; Cycle-1, lanes T&S) after 72 
hours prior to SEC also showed a similar increase in the amount of LFAOs compared to 
seed alone (Figure 23 E; lane seed).  More importantly, the seeded sample  (Figure 23E; 
Cycle-1, lanes T&S) showed a replicated LFAO (R-LFAO) band centered around ~100 
kDa after Cycle-1, which was also consistent with our previous observation that 
replication led to the formation of higher molecular weight species of LFAO (~80-110 
kDa) (Chapter IV.2; Figure 17).
113
  SEC fractions 16 and 17 (Figure 23 E; Cycle-1, lanes 
1&2) also showed the presence of isolated R-LFAOs.  Moreover, a high molecular 
weight band, which failed to enter the gel and was likely fibrils, was also observed after 
72 hours in seeded samples (Figure 23 E; Cycle-1, lane T).  
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Figure 23. Cyclic Propagation of LFAOs.  A, B & C show LFAO propagation cycles 
after 72, 96 and 212 hours, respectively, monitored by SEC fractionation on a Superdex 
75 column.  The SEC profile comparison of seeded sample (solid line) with seed alone 
(dotted line) was shown to indicate the quantitative increase in the amount of LFAOs 
after each cycle.  D) The quantitative estimate of LFAOs’ fold increase after each cycle 
was calculated by comparing the SEC peaks of seeded with seed alone.  E) Immunoblot 
of LFAO samples after each amplification cycle.  Lane seed shows the LFAO used as 
seed for cycle 1.  Lane C shows an Aβ42 control without any seeds for each cycle at 
indicated time points.  Lanes T & S show the total and supernatant of the seeded sample 
after centrifugation at 19,000 x g to remove any fibrils after each amplification cycle.  
Lanes 1 & 2 shows replicated LFAOs in SEC fractions 16 & 17 after Cycle-1.  
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The fibril band was absent in the supernatant (Figure 23E; Cycle-1, lane S), 
further confirming that these bands were indeed fibrils.  The presence of some fibrils is 
expected due to on-pathway fibril formation reactions (monomer-monomer interactions) 
that occur simultaneously to monomer-LFAO interactions.  For the second propagation 
cycle (Cycle-2), the SEC fractionated R-LFAOs from Cycle-1 (fraction 16, lane 1; Figure 
23 E) were used as seeds (50% v/v) to 50 μM Aβ42 monomers at room temperature for 
96 hours (Figure 23 B).  A 50% v/v was used for seeding in Cycle-2 because the precise 
concentration of isolated R-LFAOs was difficult to calculate due to dilution.  After 
several screens, we increased the incubation time from 72 to 96 hours for Cycle-2, 
because the amount of seeds used were approximately 2/3 less than in Cycle-1.  After 96 
h, the supernatant of the seeded sample was subjected to SEC fractionation, and fractions 
16 and 17 were collected and compared to the seed alone (Figure 23 B; Cycle-2).  The 
seeded sample in Cycle-2 showed a ~2.3 fold increase after 96 hours (Figure 23D; Cycle-
2).  Interestingly, the seed alone showed a faint R-LFAO band centered around ~ 100 
kDa (Figure 23 E; Cycle-2, lane S), but fractionation did not lead to detectable amounts 
on immunoblot (data not shown).  The amplification cycle was further continued using 
fraction 16 of Cycle-2 as seed (50% v/v), but the incubation time was increased to 212 
hours in order to be able detect the replicated oligomers.  No amplicafication was 
observed even after 212 hours (Figure 23 D; Cycle-3).  As expected, the corresponding 
immunoblot did not show the presence of any R-LFAOs (Figure 23 E; Cycle-3, lane S).  
Based on the SEC profiles, the concentrations of seed used in Cycles -2 & -3 were 
approximately estimated to be around 0.29 μM (0.59%) and 0.025 μM (0.05%) 
respectively (data not shown).  
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The data clearly indicates that LFAOs undergo significant amplification after 
Cycle-1, but amplification efficiency decreases by ~35% after Cycle-2 and becomes 
insignificant after Cycle-3.  There could be two possible reasons for this behavior: a) R-
LFAOs are less efficient in amplification because of their larger size as compared to 
original LFAOs (~100 kDa versus 56-80 kDa for LFAOs and R-LFAOs respectively).  A 
similar observation was reported for PrP
Sc
 protein by Castilla et al., in which they showed 
that larger aggregates of PrP
Sc
 formed above 100 °C are less efficient for amplification as 
compared to parent PrP
Sc
.
115
  b) The amount of seeds used in Cycle-3 is well below the 
threshold concentration of seed (minimum amount required to self-propagate).
101, 117
 
Comparison of Seeding Efficiency of R-LFAOs vs. Parent LFAOs 
First we wanted to analyze the effect of size difference between LFAOs and R-
LFAOs on self-propagation.  Cycle-2 of LFAO amplification, in which R-LFAO, the 
larger oligomeric band (~80-110 kDa) of native LFAOs, was used as a seed, showed less 
efficient propagation as compared to Cycle-1, which used parent LFAOs (~56-80 kDa).  
The R-LFAOs were generated as previously described (see Materials & Methods).  In 
order to see whether larger aggregates are less efficient in promoting amplification, the 
same LFAO propagation procedure was repeated using 2% of SEC isolated R-LFAOs as 
seed for 20 μM buffered Aβ42 monomer.  The same percentage of original LFAO seed 
was also used as a control for the comparison of propagation efficiency with R-LFAOs.  
After 96 hours, both samples were subjected to immunoblotting and SEC. Additionally, 
to keep the conditions of the amplification cycle constant, samples were incubated for 96 
hours instead of 72 hours.  In Figure 24 (inset), lanes 2 and 4 show the control and R-
LFAOs samples after 96 hours respectively.  The immunoblot band intensity for both the 
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samples was identical.  However, quantitative SEC comparison showed a ~2.4 and ~1.6 
fold increase for the control and R-LFAO seeded sample, respectively (Figure 24).  More 
interestingly, R-LFAOs showed a ~33 % decrease in amplification efficiency as 
compared to control, which is identical (~35 %) to the decrease observed after Cycle-2 of 
LFAO amplification (Figure 32).  The data clearly indicates that larger ~80-110 kDa R-
LFAOs are less efficient in amplification as compared to native LFAOs, further 
complementing our previous observation.    
Physiochemical Differences and Similarities between LFAOs and Prions 
effect of temperature on LFAO propagation and other physiochemical properties. 
Previous studies on PrP
Sc
 protein replication and propagation have shown that high 
temperatures can promote the formation of larger aggregates, which can greatly reduce 
the amplification efficiency.
115
  To investigate whether LFAOs showed a similar 
property, the effect of temperature on LFAO propagation was explored.  A 7 μM 
incubation of LFAOs was heated for 5 min at specific temperatures ranging between 10 
and 120 
o
C and subjected to DLS analysis.  Small aliquots of these samples were then 
subjected to immunoblotting (Figure 25A).  A significant shift towards higher molecular 
weight was observed for samples heated at 80, 100 and 120
 
°C (Figure 25A, lanes 2, 3, & 
4) as compared to control unheated LFAOs (Figure 25A, lane 1).  The 100 and 120
 
°C 
samples showed a large disperse band ranging from 80 to >260 kDa. 
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A similar shift towards larger size was also observed for 80, 100 and 120
 
°C 
samples in DLS (Figure 25 B).  The heat-treated LFAO samples at 80 (dark grey), 100 
(grey)  and 120
 
°C (light grey) showed monodisperse peaks centered at ~11 , ~18 and ~ 
37 nm in diameter, respectively, all of which were larger in diameter than the unheated 
LFAO sample (black peak;  ~7 nm in diameter) (Figure 25B).  It is evident that an 
increase in temperature promotes larger aggregates of LFAOs.  The treatment of LFAOs 
at lower temperatures (20-60 
o
C) did not cause any changes compared to the unheated 
LFAO sample in either DLS or immunoblots (data not shown).  The CD analysis showed 
 
Figure 24. Comparison of Propagation Efficiency of Parent LFAO vs. R-LFAO.  
20 μM Aβ42 was incubated with 2% (molar ratio) parent LFAO (black bar) and 
replicated LFAO (R-LFAO, grey bar) at room temperature for 96 hours.  After 96 
hours both the samples were subjected to SEC and quantitative fold increase was 
calculated by comparing the SEC profiles.  The inset shows an immunoblot of 
LFAO and R-LFAO seeded sample after 96 hours.  Lanes 1 & 2 shows parent 
LFAO seed alone and 96 hour seeded sample, respectively.  Lanes 3 & 4 shows R-
LFAO seed alone and 96 hours seeded sample, respectively.     
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an increase in β-sheet content, characterized by a minimum at 216 nm, with increasing 
temperature (Figure 25 C).  This observation was consistent with the report by Gursky 
and colleagues, who showed that heating Aβ40 at higher temperatures caused an increase 
in β-sheet content, suggesting further oligomerization and aggregation.118  Similar reports 
have also been reported for other amyloidogenic proteins.
119
 
Next, we compared the seeding and propagation efficiency of 80, 100, and 120 °C 
heated LFAO sample with unheated LFAO sample.  For seeding and propagation, 20 μM 
freshly purified, seed-free Aβ42 was incubated at room temperature for 72 hours either 
with 0.4 μM (2% molar ratio) unheated LFAO as a control or with LFAOs that had 
previously been heated to 80, 100 or 120
 
°C.  Immunoblot lanes 2, 4, 6, and 8 show the 
comparison of propagation efficiency between unheated and 80 and 100
 
°C heated LFAO 
samples (Figure 25 D).  The quantitative fold increase, determined by comparing the SEC 
peaks of seeded sample and seed alone, and indicated a ~2.5 fold increase for the 
unheated LFAO sample (Figure 25E, unheated).  In contrast, the 80, 100 and 120
 
°C 
heated LFAO samples showed 1.4, 0.7 and 0.4 fold increases respectively (Figure 25 E; 
80, 100, & 120
 
°C), indicating a decrease in amplification/propagation efficiency with the 
increase in temperature.  A statistical analysis of variance (ANOVA) on the data 
indicated  >90% (Figure 25 E, 80 °C; ●) and  >99% (Figure 25 E, 100 & 120 °C; **) 
significance in the difference between the seeding efficiency of unheated LFAO and 80, 
100 and 120 °C heated LFAO after 72 hours.   
The data also suggest that, although they do so with diminished efficiency, even 
the larger aggregates of LFAO were able to undergo self-propagation, as no fibrils were 
observed.  This clearly demonstrates that the entire propagation process occurred along 
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the off-pathway, as we had hypothesized (see chapter IV.2.).  The data further indicates 
that higher temperatures can induce the formation of larger aggregates and reduce the 
amplification efficiency, a behavior similar to PrP
Sc
 propagation.
115
 
determination of LFAOs’ threshold seed concentration and seeding efficiency. A 
minimum critical concentration of seeds is required for the initiation of polymerization in 
nucleation-dependent aggregation reactions.
101, 117
  In order to determine the threshold 
seed concentration for LFAOs to undergo self-propagation, 30 μM buffered Aβ42 was 
incubated with 0.2, 2, and 20% (molar ratio) LFAO seed at room temperature for 212 
hours.  Small aliquots of samples were removed at 72, 144 and 212 hours and subjected 
to SEC and immunoblotting to observe the quantitative increases in the amount of 
LFAOs (Figure 26).  
Immunoblot lanes 1, 2, and 3 show 0.2, 2, and 20% LFAO seed alone, 
respectively (Figure 26 A), and lanes 4, 5, and 6 show 0.2, 2, and 20% LFAO seeded 
sample after 212 hours, respectively (Figure 26 A).  A significant increase in the amount 
of LFAOs was observed in the immunoblot for the 0.2% seeded sample (Figure 26 A, 
lane 4), as compared to the seed alone (Figure 26 A, lane 2), which was undetectable 
after 212 hours.  The quantitative increase in LFAOs after each time point was calculated 
by comparing SEC peaks of seeded sample versus seed alone (Figure 26 C).  Figure 26 B 
represents the SEC profiles of 0.2 (continuous line), 2 (dotted line), and 20% (dashed 
line) seeded samples after 212 hours respectively.   
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The reaction seeded with 0.2% LFAOs showed a ~6 fold increase as compared to 
~2 fold increases by 2 and 20% seeded reactions after 212 hours (Figure 26 C).  The 
0.2% sample also showed a significant increase in LFAOs after 72 and 144 hours, but the 
maximum efficiency was observed only after 212 hours (Figure 26 C).  Statistical 
Figure 25. Effect of Temperature on LFAOs.  A) Immunoblot showing LFAOs 
heated at different temperatures.  Lane 1 shows unheated LFAO sample as a control.  
Lanes 2, 3, & 4 show LFAOs heated at 80, 100 and 120 °C, respectively.  The 
increase in LFAO size after heating is shown by double arrows.  B) DLS analysis of 
LFAOs heated at different temperatures.  C) CD spectral analysis of LFAOs heated 
at different temperatures.  D) Immunoblot showing a comparison of propagation 
efficiency of unheated vs. 80, 100 & 120 °C LFAOs after 72 hours.  Lanes 1 and 2 
show unheated LFAO seed alone and seeded sample, respectively.  Lanes 3, 5 & 7 
represent 80, 100 & 120 °C heated 0.4 μM (2% molar ratio) LFAO seed alone, 
respectively, while lanes 4, 6 & 8 represent 20 μM Aβ42 incubated with 0.4 μM (2% 
molar ratio) 80, 100 & 120 °C heated LFAO seeds, respectively.  E) Determination 
of LFAOs’ quantitative fold increase, determined by comparing the SEC profiles of 
the unheated, 80, 100 and 120 °C heated LFAO seeded samples with seed alone; ● 
and ** represent 90 and >99.9% significance, determined via ANOVA. 
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analysis on the data indicated >99.9% (Figure 26 C; ***) confidence in the increase of 
LFAO amount for 0.2% as compared to 2 and 20% after 212 hours.  All attempts to 
detect LFAOs in 0.02% (molar ratio) seeded samples by SEC and immunoblots were 
unsuccessful (data not shown); indicating that this seed concentration was below the 
threshold of optimal seeding efficiency.  
Collectively, the data show that 0.2% (molar ratio) LFAO is the most efficient 
seed concentration for promoting propagation to an exceptionally significant limit, 
allowing for easy detection by SEC and immunoblots.  Furthermore, the data indicate that 
the threshold seed concentration of LFAOs required to initiate propagation for 30 μM 
Aβ42 is ~0.06 μM (270 ng/mL), below which replication is experimentally undetectable.  
The data further explain our observation that Cycle-3 of the LFAO 
propagation/amplification (Figure 23 C), which was initiated by 0.025 μM seed, 
completely failed to show any propagation, as the LFAO concentration was below the 
threshold concentration determined here (0.06 μM). 
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Figure 26. Determination of LFAOs’ Threshold Seed Concentration and Seeding 
Efficiency.  A) Immunoblot of 30 μM Aβ42 seeded with 0.2, 2, and 20% (molar 
ratio) LFAO seeds after 212 hours.  Lane C shows control Aβ42 incubated alone 
after 212 hours.  Lanes 2, 3, and 4 represent 0.2, 2, and 20% (molar ratio) LFAO 
seeds alone, respectively.  Lanes 4, 5, and 6 represent 0.2, 2, and 20% (molar ratio) 
LFAO seeded sample after 212 hours, respectively.  Single and double arrows 
indicates original LFAO seeds at ~56-70 kDa and R-LFAO bands at ~80-110 kDa 
after propagation, respectively.  B) SEC profile of 0.2, 2, and 20% (molar ratio) 
LFAO seeded sample after 212 hours.  C) Determination of LFAOs’ quantitative 
fold increase at different time points, by comparing the SEC peak profiles of the 0.2, 
2, and 20% (molar ratio) LFAO seeded sample with seed alone; ●, *, **, and *** 
represents 90, >95, >99 and >99.9% significance based on analysis of variance using 
ANOVA.  
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Discussion 
In prion diseases, self propagation of the misfolded PrP
Sc
 form by a ‘template-
assisted corruptive’ mechanism is a well known phenomenon.77  Many recent studies on 
prions have shown that it is possible to replicate the in vivo infectious mechanism under 
in vitro conditions using the PMCA method.
112, 114, 116
  In PMCA, a small amount of 
endogenous PrP
Sc
 seed can be amplified with complete structural faithfulness upon 
addition to native PrP using successive cycles of sonication and incubation to an amount 
easily detectable for diagnostic purposes.
112, 115
  
In the AD field, prion type propagation is an emerging hypothesis, and recent in 
vivo studies have demonstrated this phenomenon in transgenic mouse models.
88
  
Recently, Stόhr and coworkers have shown that synthetic Aβ can act as prions and 
undergo self-propagation and migration upon inoculation into mouse brains.
89
  In the 
previous results section (Chapter IV.2.), we have shown that LFAOs can also self-
propagate by converting monomers into more LFAOs at the expense of fibrils, displaying 
a behavior similar to prions, which forms the first such in vitro observation.
113
 
Similarity between LFAO and Prion Propagation  
In this section, we have presented the similarities and dissimilarities between 
prion and LFAOs propagation.  A method similar to PMCA was used for LFAO 
propagation and indicated that small amounts of LFAOs, upon monomer addition, 
undergo significant amplification/propagation like prions during Cycle-1, but 
amplification/propagation efficiency decrease by ~32% for Cycle-2, due to the formation 
of R-LFAOs.  Propagation becomes insignificant after Cycle-3.  Interestingly, the R-
LFAOs, when used as a seeds for the propagation experiment also showed a ~32 % 
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decrease in amplification efficiency as compared original LFAO seed, clearly indicating 
that the higher molecular band of LFAOs is less efficient in promoting propagation.  
Interestingly, LFAOs, when subjected to higher temperatures, showed the formation of 
larger aggregates, which are less efficient in promoting amplification when used as a 
seed, a behavior similar to prions.
115
  More importantly, data clearly indicated a similarity 
in the propagation behavior of LFAOs and prions in in vitro.  LFAO propagation has an 
advantage in that it is very straight forward, not requiring optimization of any special 
parameters as in the PMCA method of prion amplification.  
LFAO Threshold Seed Concentration 
We could not detect any amplification of LFAOs after Cycle-3, which could be 
due to the seed amount being well below the threshold concentration necessary to initiate 
such a process.
101, 117
  Seed concentrations below 0.2% failed to show any propagation 
efficiency and were completely undetectable under experimental conditions.  Based on 
this analysis, the LFAO threshold seeding concentration was determined to be ~60 nM 
for 30 μM Aβ42 , which is 2.5 times less than the ~150 nM required to initiate in vitro 
propagation of prions.
117
  
Significance 
These findings are significant as they are the first comprehensive demonstration 
of in vitro prion type propagation of Aβ oligomers.  So far, LFAOs are the only 
biophysically characterized in vitro oligomers that act as ‘prions’.  This Aβ prion 
propagation has immense practical implications and can be utilized to amplify small 
amounts of endogenous seed to amounts feasible for biophysical and structural 
characterization using exogenous monomers.  The early detection of similar, self-
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propagating oligomeric species, having similar conformation as LFAOs, in plasma and 
CSF could be used as a potential biomarker for diagnostic purposes in AD.  Future 
studies will be directed towards elucidating LFAOs prion type propagation behavior in in 
vivo conditions. 
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CHAPTER V 
CONCLUSIONS AND FUTURE WORK 
Conclusion-1: All Oligomeric Species Need not Be Formed along the  
Obligatory On-pathway: Physiological Significance 
LMW oligomers are believed to be the primary toxic species involved in the 
etiology of AD.  As a result of their increased significance in AD pathology and lack of 
structural information about these oligomers, many research groups have shifted their 
primary focus to the identification and characterization of both in vivo and in vitro Aβ 
oligomers.  This focused approach towards oligomers resulted in several new important 
findings. So far, it has been believed that oligomers are formed as transient intermediates 
during the fibril formation on-pathway.  However, the observation of polymorphism 
among Aβ aggregates indicated the possibility of multiple Aβ aggregation pathways.  
Only a few observations have been reported indicating that Aβ oligomers may formed 
along an alternate pathway completely different from classical nucleation-dependent on-
pathway. 
41, 46, 75, 96, 120
  
The significance of understanding multiple pathways lies in the fact that if some 
oligomers are formed along the off-pathway, they might have a longer self half-life 
compared to the on-pathway species, resulting in prolonged toxicity to neuronal cells.  
The data presented here further strengthen the multiple pathways hypotheses and indicate 
that both CMC as well as Aβ:fatty acid/lipid ratios play significant roles in dictating the 
pathway of Aβ aggregation and forming off-pathway oligomers (Chapter IV.1).  
Interestingly, these off-pathway oligomers seem to possess unique physiochemical 
properties compared to their on-pathway counterparts.   
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The Aβ peptide is amphipathic in nature, as result of which it has high affinity for 
membranes, which have in turn also been shown to affect the early stages of Aβ 
aggregation.
69-71, 121, 122
  GM-1 gangliosides containing lipid rafts as well anionic 
phospholipids have also been shown to increase the rate of Aβ aggregation.72, 123-126  
Apart from lipids, oligomers generated by fatty acids like lauric acid, oleic acid and 
arachidonic acids were shown to inhibit hippocampal LTP in Tg2576 mice model.
37
  
Interestingly, other amyloidogenic proteins like α-synuclein, apolipoprotein C-II and 
prions have also been shown to display unique behavior in the presence of various 
interfaces.
127-130
  Recently, it was shown that the misfolded, infectious PrP
Sc 
form of prion 
protein obtained from the conversion of normal, bacterially expressed, recombinant prion 
protein undergoes propagation only after interacting with a membrane anionic 
phosphatidyl surface.
131
  All of the observations and data presented here clearly indicate 
the physiological significance of lipid- and fatty acid-induced interfacial aggregation of 
Aβ, which could generate structurally and biologically unique oligomers that may be 
important in the AD pathology. 
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Conclusion -2: Prion Type Self-propagation: A Unique Property  
of ‘Off-pathway’ Oligomers 
The prion-type corruptive template-assisted mechanism of infectivity is a newly 
emerging hypothesis among neurodegenerative diseases.  Recent studies and finding have 
shown that synthetic as well as brain-derived Aβ can undergo prion type propagation and 
promote acceleration of disease in mouse models.
88, 89, 132
  However, none of the reports 
demonstrate the molecular aspects of Aβ displaying prion characteristics.  Previous 
studies have shown that in vitro Aβ oligomers like PFOs and FOs can display prion type 
behavior, but one important drawback of all these oligomers is that they are not 
biophysically well characterized, which is a limiting factor for understanding the details 
of the mechanism.
85, 86
  One of the most significant findings of our studies is that we have 
shown that a unique, off-pathway, in vitro oligomer called LFAO, generated in the 
presence of fatty acid interfaces and biophysically well characterized, can undergo prion-
type self propagation, quantitatively converting more monomers into toxic oligomers at 
the expense of fibrils.
113
  Moreover, LFAOs can undergo similar in vitro amplification as 
has been shown for prions using the PMCA method.
112, 114
  All these data and previous 
findings clearly indicate a common link between AD and prion toxicity mechanisms, 
which may be the underlying mechanism among many neurodegenerative disorders. 
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Future Work 
Future studies will be directed towards elucidating the structure of LFAOs using 
biophysical techniques like Fourier transform infrared (FTIR) spectroscopy, mass 
spectrometry etc., which will provide a better understanding of their propagation 
mechanisms and help to further explore the similarities/dissimilarities between LFAOs 
and other known in vitro oligomers, on-pathway intermediates and fibrils.  
The efficiency of LFAOs to cross seed and propagate other proteins will also be 
explored using similar experimental methodology as used for LFAO propagations.  These 
proteins will include mutant forms of Aβ42 as well as both wild type and mutant forms of 
Aβ40 involved in both AD and cerebral amyloid angiopathy (CAA).  In addition, cross 
seeding with Parkinson’s-associated α-synuclein will be also investigated.  This study 
will help to explore whether all these neurodegenerative disorders are interconnected and 
whether one can increase the chance of occurrence or severity for others. 
Finally, toxicity of LFAOs will be explored on human neuroblastoma cells using 
the XTT reduction assay.  Furthermore, we will also explore the effect of LFAOs on NF-
кB activation, which is involved in A -induced endothelial adhesion and transmigration. 
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